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The cancer stem cell hypothesis posits that cancer stem cells (CSCs) are the driving force 
behind tumour progression and metastasis, making them ideal therapeutic targets. Previous 
research identified Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) as a 
marker of CSCs in colorectal cancer (CRC). However, it is not known whether more than one 
CSC population exists in CRC. Identifying and targeting CSCs in CRC is important for 
effective treatment of cancer patients. Here, I show that Keratin-19 (K19) labels intestinal 
CSCs in mouse tumours that recapitulate the early stages of CRC. Moreover, selective ablation 
of Lgr5 has no effect on tumour initiation or growth. These results demonstrate additional CSC 
populations exist besides those labeled by Lgr5, which are important for tumour initiation and 
growth. Consequently, these findings have important clinical implications for the development 
of new therapies targeting CSCs.  
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Chapter 1  
INTRODUCTION 
 
1.1 The Healthy Colon 
1.1.1  Intestinal anatomy and function  
The mammalian intestinal tract can be divided into the small intestine and colon, which are 
two anatomically and functionally distinct segments (Barker et al., 2010). These segments 
share the same basic structure: an outer, middle and inner layer (Barker et al., 2010). The outer 
layer consists of smooth muscle that is innervated by the enteric nervous system (Barker et 
al., 2010). This layer is responsible for rhythmic peristaltic movements that direct food along 
the intestine (Barker et al., 2010). The middle layer consists of connective or stromal tissue 
(Barker et al. 2010). This tissue contains nerves, lymphatic vessels and capillaries which 
transport absorbed nutrients from the third structure, the innermost layer (Barker et al., 2010). 
The inner layer is composed of an absorptive epithelial lining called the mucosa (Barker et al., 
2010). However, the architecture of the small intestine (duodenum, jejunum and ileum) and 
colon varies significantly reflecting their distinct functions in vivo (Barker et al., 2010). The 
luminal surface of the small intestine consists of a sheet of epithelial cells which are organized 
into numerous finger-like protrusions called villi that project into the lumen (Clevers, 2013). 
These villi maximize the available surface area for absorption, reflecting the major function 
of the small intestine - absorption of nutrients and minerals (Clevers, 2013). Each villus is 
surrounded at the base by multiple epithelial invaginations termed the crypts of Lieberkühn. 
These crypts were named after the scientist who discovered them - Jonathan Nathanael 
Lieberkühn (1711-1756) (Clevers, 2013). He injected wax into the small intestine and colon 
to reveal anatomical structures (Clevers, 2013). In contrast, the major function of the colon is 
dehydration and waste removal (Clevers, 2013). This is reflected by an essentially flat mucosal 






Figure 1 | Anatomy of the small intestine and colon. The intestinal tract is divided into two 
anatomically and functionally distinct segments: the small intestine (duodenum, jejunum, 
ileum) and colon. The colonic epithelium contains an essentially flat mucosal surface with 
multiple crypts that penetrate deep into the underlying submucosa. In contrast to the relatively 
flat surface of the colonic epithelium, the intestinal epithelium contains many finger like 
projections known as villi, surrounded by crypts. These anatomical differences reflect their 
differences in function, as the colon functions to compact stool and the small intestine 
functions to absorb nutrients. Cross sections of the colonic vs intestinal tissue highlight these 
differences. Moreover, each layer of the intestinal tract: outer, middle and inner is clearly 
defined. This figure was originally published online in Mayo Foundation for Medical 
Education and Research. [https://www.mayoclinic.org/colon-and-small-intestine/img-
20008226] and the Department of Zoology and Environmental Management, Faculty of 
Science, University of Kelaniya, Sri Lanka. Gastrointestinal histology. 2018 
[http://science.kln.ac.lk/depts/zoology/index.php?option=com_content&view=article&id=4
6&Itemid=46]. The figure is being reproduced for educational purposes only and not for any 
commercial use. Figure is included in the M.Sc. dissertation with attribution.   
 
1.1.2  Intestinal architecture  
The epithelial lining of the intestine and colon is subjected to extremely harsh environmental 
conditions (Barker et al., 2012). As such, it is highly susceptible to mechanical-, chemical- and 
pathogen-driven insults (Barker et al., 2012). This imposes a need for continuous renewal of 
the simple columnar cells that line the villi and crypts (Barker et al., 2012). Structurally, the 
intestinal epithelium is highly regulated, with up to ten crypts generating over 250 new 
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epithelial cells per day (Clevers, 2013) allowing for the entire epithelium to renew itself every 
3-5 days for the duration of our lifetime (Leblond & Stevens, 1948). Due to the harsh 
conditions that exist in the intestinal lumen, this extreme turnover rate is necessary to maintain 
intestinal tissue homeostasis (Barker et al., 2010).  
 
The cells responsible for driving tissue regeneration are vigorously proliferating epithelial cells 
– known as intestinal stem cells (ISCs) that reside at the bottom of crypts (Barker et al., 
2012).  The ISC population is capable of self-renewal and asymmetric division and gives rise 
to rapidly expanding progenitors known as transit amplifying (TA) cells (Barker et al., 2012). 
TA cells in the crypt divide and move toward the crypt/villus border to differentiate into six 
main epithelial cell types: enterocytes, enteroendocrine cells, goblet cells, tuft cells, Paneth 
cells (small intestine) and deep secretory cells (colon), whose function is outlined below 
(Figure 2) (Van der flier & Clevers, 2009). These differentiated epithelial cells continue 
migrating up the villus axis until they undergo apoptosis and are shed into the lumen of the 
intestine  (Van der flier & Clevers, 2009). The only post-mitotic cell types excluded from this 
upward mobility are the Paneth cells (small intestine) and deep secretory cells (colon) (Van 
der flier & Clevers, 2009). They migrate to the crypt base, where they reside for 6-8 weeks 
(Van der flier & Clevers, 2009).  
 
Enterocytes  
Enterocytes comprise the majority of differentiated cells found in the villi of the small 
intestine (Clevers, 2013). They are characterized by a luminal brush border and function as 
absorptive cells responsible for nutrient uptake (Clevers, 2013). Due to their cellular 
organization, they also prevent microbes from entering the bloodstream as they are tightly 
packed together forming cell-to-cell adhesions, which act as a protective epithelial barrier 
(Clevers, 2013). Enterocytes can be identified histologically by the expression of the enzyme 
alkaline phosphatase.  
 
Enteroendocrine cells 
In comparison to other differentiated cell types, enteroendocrine cells are more rare and are 
found throughout the whole crypt-villus axis (Gunawardene, 2011). Their function is to secrete 
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hormones that regulate numerous processes, such as controlling glucose levels and food intake, 
as well as signaling to empty food from the stomach (Gunawardene, 2011). They can be 




Goblet cells are found throughout the villus and secrete mucins, which function to aid in the 
lubrication of the epithelium (Clevers, 2013). Mucins serve to protect the epithelial lining from 
extreme mechanical stress that results from the movement of food through the intestine 
(Clevers, 2013). Goblet cells have also been found to secrete trefoil proteins that contribute to 
tissue repair (Mashimo et al. 1996). These cells can be identified histologically by staining for 
mucins using Alcian Blue.  
 
Tuft cells 
Tuft cells are also referred to as brush cells and are found anywhere throughout the crypt-villus 
axis (Middlehoff et al., 2017). Their exact function and importance for intestinal homeostasis 
are controversial (Middlehoff et al., 2017). However, they may act as chemosensory cells that 
detect and sense the luminal contents (Middlehoff et al., 2017). Tuft cells can be identified 
histologically through staining for a variety of different markers including Doublecortin Like 
Kinase 1 (DCLK-1) (Middlehoff et al., 2017).  
 
Paneth cells  
Paneth cells are found exclusively in the small intestine, where they reside at the base of the 
intestinal crypt (Clevers, 2013). They protect the intestinal crypt by providing microbial 
immunity through the secretion of a variety of antimicrobial peptides such as lysosomes and 
defensins (Clevers, 2013). Paneth cells may also play a role in tissue maintenance through the 
secretion of growth factors that support the ISC population (Clevers, 2013). Unlike the other 
differentiated cell types, Paneth cells are long-lived (6-8 weeks) and migrate back down to the 
crypt-villus axis as they differentiate (Clevers, 2013). They can be identified histologically by 




Deep crypt secretory cells  
Deep crypt secretory cells (DCS) are found exclusively in the colon, where they reside at the 
base of the crypt (Sasaki et al., 2016) They may represent the colonic counterpart of Paneth 
cells (Sasaki et al., 2016). DCS cells can be identified through the expression of Reg4+ (Sasaki 
et al., 2016). 
 
 
Figure 2 | The intestinal and colonic epithelium. The intestinal epithelium consists of 
crypts and villi. The crypt base contains rapidly cycling intestinal stem cells (ISCs) as well 
as transit-amplifying (TA) progenitors. The major differentiated cell types are enterocytes, 
enteroendocrine cells, goblet cells, tuft cells and Paneth cells. Except for Paneth cells, these 
cell types migrate as clonal lineages to the tip of the villi in 4-5 days where they are shed 
into the lumen. Post-mitotic Paneth cells are relatively long lived (6-8 weeks) and 
intermingle at crypt bottoms to secrete ISC niche factors and support innate immunity. In 
contrast to the small intestine the colonic epithelium has a flat epithelial surface and lacks 
Paneth cells. Instead of Paneth cells, deep secretory crypt cells are thought to be responsible 
for the ISC niche function. This figure was originally published in Nature. Vermeulen L., 
and Snippert H. J. Stem cell dynamics in homeostasis and cancer of the intestine. 2014; 
14(7), 468-480. This figure is being reproduced for educational purposes only and not for 





1.1.3  Intestinal stem cells  
 
Models of intestinal stem cell identity  
Although it is widely accepted that intestinal stem cells are multipotent adult stem cells, 
which give rise to all epithelial cell lineages, the exact identity of ISCs (location and gene 
expression patterns) is controversial. Over time, technological innovation has enabled the 
identification of multiple candidate stem cell populations and provided insight into the 
function of the ISC compartment. However, the lack of definitive markers to identify ISCs 
has been a major obstacle in the field of intestinal stem cell biology. This created a long-
lasting debate on the true identity of ISCs, which remains confusing partially due to the use 
of many different terms for the same cell or cellular processes. 
 
Previously, it was reported that ISCs can be categorized into two distinct populations: crypt 
base columnar and +4 stem cells. This led to the emergence of two opposing intestinal stem 
cell models: the stem cell zone model and the +4 model (Barker et al., 2010). The stem cell 
zone model argues that crypt base columnar (CBC) stem cells are the actual stem cells, 
which rapidly divide at the base of the crypt and are responsible for intestinal homeostasis 
(Cheng & Leblond, 1974). In contrast, the +4 model argues that the actual stem cells 
responsible for intestinal homeostasis reside at the +4 position as discovered by Potten and 
colleagues (Potten et al. 1997; Barker et al., 2010). A number of different stem cell markers 
have been proposed for each model, only to be refuted later, making this a dynamic and 





Crypt base columnar stem cells  
The first marker for CBC cells, leucine-rich-repeat containing G-protein coupled receptor 
5 (Lgr5), was identified as a Wnt target gene selectively expressed at the base of intestinal 
crypts (Figure 5) (Barker et al., 2007; Stevens and Leblond, 1947; Koo and Clevers, 2014). 
Lgr5-positive CBC cells are considered fast-cycling as they divide every day and are the 
driving force of intestinal tissue renewal (Barker et al., 2010). Several experimental 
approaches have been used to validate the stem cell-like nature of these cells that are 
outlined below, including lineage tracing, gene expression studies, stem cell activity 
assays, and in vitro organoid culture.  
 
In vivo lineage tracing using the Lgr5 marker  
The current ‘gold standard’ to identify candidate stem cells in their native 
microenvironments is lineage tracing (Barker, 2013). In this technique, a permanent 
heritable genetic mark, such as the expression of a fluorescent protein, is introduced into 
candidate stem cells (Barker, 2013). Subsequently, these marks are inherited by 
descendants of that cell enabling their characterization in the epithelium (Figure 3) (Barker, 
2013). If the presence of all differentiated lineages is observed in a single traced clone that 
is capable of long-term labelling of cell lineages, it may reveal multipotency and self-
renewal (Barker, 2013). Taken together, these characteristics fulfil the basic definition of 
a stem cell, as a cell capable of self-renewal and multipotency (Barker, 2013). The stem 
cell activity of Lgr5+ CBCs was confirmed via lineage tracing in mice, which demonstrated 
that CBC cells produced clonal ribbons containing all the major epithelial cell lineages and 
persisted for the lifetime of the mouse (Barker et al., 2007). These results validated Lgr5+ 




Figure 3 | Genetic lineage tracing using Lgr5. (A) Cre recombinase expression is spatially 
restricted by expressing it under the control of a tissue-specific promoter (Lgr5), while 
temporal restriction is achieved by fusion of a tamoxifen-responsive hormone-binding 
domain of the estrogen receptor (Cre-ERT). To visualize Lgr5 expressing cells as well as 
their progeny, the Cre construct was used in conjunction with a reporter gene LacZ. This 
reporter is ubiquitously expressed under the control of the Rosa26 promoter and placed 
downstream of a STOP codon flanked by cre recombinase recognition sites (loxp). In the 
absence of tamoxifen, the Cre enzyme is in an inactive state. Therefore, no expression of 
the reporter gene is observed due to the presence of the STOP codon upstream of the 
reporter gene. (B) However, when tamoxifen is administered the Cre enzyme is activated 
and capable of translocating to the nucleus to mediate recombination between the loxp sites 
in Lgr5 expressing cells. As a consequence, the STOP codon is excised and the cells are 
permanently marked by the reporter gene. Part of this figure was originally published in 
Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis and cancer of 
the intestine. 2014; 14(7), 468-480. This figure is being reproduced for educational 
purposes only and not for commercial use. Figure is included in the M. Sc. dissertation 
with attribution. (C) Histological analysis of LacZ activity in the small intestine of Lgr5-
CreERT;Rosa26-RLZ mice one day after induction, five days after induction (D), and 60 
days after induction (E) This figure was originally published in Nature. Barker et al. 
Identification of stem cells in small intestine and colon by marker gene Lgr5. 449(7165), 
10003. This figure is being reproduced for educational purposes only and not for 
commercial use. Figure is included in the M. Sc. Dissertation with attribution.  
 
Lgr5+ CBC stem cell expression signature  
Through a combination of microarray and proteomic experimental techniques, researchers 
were able to establish a molecular signature for Lgr5+ CBC stem cells (Munoz et al., 
2012;Van der Flier et al., 2007). Sorted intestinal Lgr5-eGFP stem cells (high eGFP 
expression) and their progeny (low eGFP expression) were analyzed to reveal 






As expected, a strong Wnt signature was present, including many Wnt target genes such as 
Achaete-scute complex homolog 2 (Ascl2), EphB2, and Tory and axis inhibition (axin)-2 
(Van der Flier et al., 2007). Interestingly, this expression profile also revealed novel 
markers of Lgr5+ CBCs including Olfactomedin 4 (Olfm4) and SPARC related modulator 
calcium binding 2 (SMOC2), as well as ring finger 43 (Rnf43) (Van der Flier et al., 2007). 
 
Regulation of CBC stem cell activity and fate  
Many of the genes identified from the Lgr5+ CBC stem cell expression signature have been 
used to provide functional insight into the regulation of intestinal stem cell activity and fate 
in vivo. In particular, ASCL2 was found to be highly upregulated in the Lgr5+ stem cell 
fraction and was identified as a critical regulator of intestinal stem cell fate (Van der Flier 
et al., 2009). ASCL2 is commonly known as a transcription factor that promotes neuroblast 
differentiation. However, conditional ablation of ASCL2 in the intestinal epithelium 
resulted in a rapid loss of the stem cell compartment (Van der Flier et al., 2009). Two other 
genes that were found to be highly expressed in stem cells were Rnf43 and Troy (Barker, 
2013). These genes play an important role in regulating endogenous Wnt signaling which 
is critical in the maintenance of the stem cell compartment. Accordingly, Lgr5 was 
identified as a component of the Wnt signaling complex at the plasma membrane (Barker, 
2013). Lgr5 recruits secreted Wnt agonists (roof plate-specific spondin (R-spondin) 1-4), 
thus amplifying canonical Wnt signaling and ensuring stem cell homeostasis in vivo 
(Barker, 2013).  
 
In vitro culture of Lgr5+ CBC stem cells 
Further proof of Lgr5 labelling a stem cell population arose from the development of a 
novel in vitro method known as organoid culture. In this method, single Lgr5+ CBC cells 
were isolated from Lgr5-eGFP reporter mice using fluorescence activated cell sorting 
(FACS) and plated in a Matrigel-based three-dimensional culture system (Sato et al., 2009). 
The Matrigel is supplemented with media that contains a cocktail of growth factors found 
in the endogenous stem cell niche including: Noggin (a bone morphogenic protein 
inhibitor), R-spondin (Wnt agonist), epidermal growth factor (EGF) and Notch ligand (Sato 
et al., 2009). This generates self-renewing epithelial organoids also known as “mini-guts” 
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that are organized into crypts (containing CBC cells intercalated with Paneth cells) and a 
villus-like region (containing differentiated cell lineages) (Figure 4) (Sato et al., 2009). 
This system was also adapted to culture the colonic epithelium. However, these cultures 
require WNT3A in the media, most likely reflecting differences in the stem cell niche 




Figure 4 | Generation of organoids via intestinal stem cell culture. Isolated intestinal 
crypts containing Lgr5+ CBC stem cells or purified Lgr5+ CBC stem cells are plated into 
Matrigel containing Noggin, R-spondin1, EGF and Notch ligand. This results in the 
generation of self-renewing epithelial organoids organized into crypt and villus like 
domains. The crypts contain stem cells intercalated with Paneth cells at their base, while 
the villi contain differentiated cell lineages. This protocol was adapted for culturing the 
colonic epithelium, although these cultures require exogenous WNT3A. This figure was 
originally published in Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in 
homeostasis and cancer of the intestine. 2014; 14(7), 468-480. Modified figure shown here 




+4 stem cells  
A number of genes have been reported to selectively identify the +4 stem cell position 
using in vivo lineage tracing including B cell-specific Moloney murine leukemia 
integration-1 (BMI1), keratin-19 (K19) and homeodomain-only (HOPX), which are briefly 







BMI1 was first implicated in regulating hematopoietic and neural stem cell regulation 
through encoding a component of the Polycomb repressor complex (Sangiorgi & Capecchi, 
2008). However, analysis of BMI1 expression in the small intestine using in situ 
hybridization revealed that it was predominantly expressed at the +4 ISC position 
(Sangiorgi & Capecchi, 2008). This was further validated using a Bmi1-eGFP reporter 
mouse model (Tian, H. et al 2011), as well as in vivo fate-mapping studies using a Bmi1-
CreERT/R26R-lacz mouse model. These experiments demonstrated that BMI1+/ +4 
position cells produced clonal ribbons containing all the major epithelial cell lineages and 
persisted for the lifetime of the mouse (Tian, H. et al 2011), thus validating BMI1+/ +4 
cells as self-renewing multipotent adult ISCs. Additionally, when BMI1+ cells were 
ablated in vivo, epithelial renewal was prevented, suggesting BMI1+ ISCs play an 
important role in intestinal homeostasis (Tian, H. et al 2011). Further evidence 
demonstrated that isolated BMI1+ cells could generate epithelial organoids in culture that 
capitulated functional intestinal tissue (Yan et al., 2012), providing support that BMI1 
labels an ISC population.  
 
K19 
Keratin-19 (K19) was first implicated as a cytokeratin (a multigene family of intermediate 
filaments), critical in the maintenance of the cytoskeleton but expressed in different 
lineages in the epithelium (Moll et al., 1982). To investigate the role of K19 in the small 
intestine and colon, a K19-mApple reporter mouse was generated. Upon histological 
analysis of the small intestine and colon, K19-mApple was expressed at the +4-position 
extending up the isthmus, labelling a population of cells including long-lived stem cells 
that were distinct from rapidly cycling Lgr5+ CBC stem cells. Of note, unlike BMI1, K19 
is expressed in both the small intestine and colon (Asfaha et al., 2015). Furthermore, 
genetic lineage tracing experiments using K19-BAC-CreERT;R26-LacZ mice revealed 
labelled cells expanded clonally and persisted for the lifetime of the mouse, consistent with 






HOPX was first implicated in regulating developmental processes as the gene encodes an 
atypical homeobox protein. However, analysis of HOPX expression in the intestine using 
HOPX-Lacz reporter mice revealed it labels a +4 position ISC population that is quiescent 
and radiation-resistant (Takeda et al., 2011). This was further validated through in vivo 
lineage tracing studies using HOPX-CreERT;R26R-Lacz mice (Takeda et al., 2011). These 
studies revealed reporter gene activation at the +4 position followed by the production of 
clonal ribbons containing all the major epithelial cell lineages that persisted for the lifetime 
of the mouse (Takeda et al., 2011). This indicated that HOPX labels a multipotent, self-
renewing adult ISC. When the progeny of HOPX+ cells were analyzed using expression 
profiling, Lgr5 and other CBC genes were found to be highly expressed. This suggested 
that HOPX is capable of giving rise to Lgr5+ CBC cells. Of note, when Lgr5+ CBC stem 
cells were cultured they gave rise to HOPX+ cells (Takeda et al., 2011). These findings 
support a unique model of ISC identity, whereby stem cell populations may interconvert.  
 
Figure 5 |Markers & characteristics of intestinal stem cells. +4 ISC can be identified 
through the markers K19, BMI1 and HOPX. This stem cell population is typically 
characterized as label retaining, quiescent and damage resistant. CBC stem cells can be 
identified through the expression of Lgr5 and OLFM4. This stem cell population is 
typically characterized as proliferative and damage sensitive. This figure was originally 
published in Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis 
and cancer of the intestine. 2014; 14(7), 468-480. Modified figure shown here is 








Current view on intestinal stem cell identity  
Although specific markers have been identified for both the CBC and +4 stem cell 
populations, neither model has been definitively true. Recently, a more plastic model of 
stem cell identity has emerged. In this model, the crypt base contains two types of ISCs (1) 
the CBC stem cells that act as a dedicated and active ISC population responsible for daily 
epithelial homeostasis, and (2) the relatively quiescent +4 cells, which act as a secondary 
“reserve” stem cell population capable of activating upon tissue injury. Furthermore, this 
model suggests that cells residing in the lower portion of the TA compartment may 
dedifferentiate to acquire stem cell properties in the case of catastrophic injury to the crypt 
base. Accordingly, it has been proposed that many of the markers discussed above define 
pools of dedicated or reserve ISC that are selectively activated in response to various 
injuries. Importantly, many irradiation-induced injury models have provided important 
mechanistic insight into this theory. In one study, short-term loss of Lgr5+ CBC cells 
through targeted conditional ablation in vivo, revealed no negative effects on the intestinal 
epithelium despite the critical role of CBC cells in homeostasis (Tian et al., 2011). This 
suggested that another damage-resistant “reserve” stem cell may be capable of maintaining 
intestinal homeostasis (Tian et al., 2011). Based on the inherent characteristics of +4 ISCs 
such as quiescence and radiation-resistance, they are the likely reserve stem cell candidates 
(Yan et al., 2012). Moreover, there is evidence that BMI1 as well as K19 label a reserve 
stem cell population as in vivo lineage tracing from BMI1 (Tian et al., 2011) and K19 
(Asfaha et al., 2015) was observed following targeted ablation of the Lgr5+ CBC stem cell 
population or radiation injury. Challenging the traditional models of ISC identity, these 
findings support a unique model whereby epithelial homeostasis is maintained by a 






1.1.4 Signaling pathways involved in intestinal homeostasis 
The maintenance of intestinal structure and function depends upon a delicate balance of 
cell proliferation, migration and apoptosis that must be carefully regulated. These processes 
are regulated by controlling gene expression through four main signaling pathways: Wnt, 




The Wnt signaling pathway plays an essential role in the maintenance of cellular hierarchy 
throughout the intestinal and colonic epithelium. A gradient of Wnt activity is observed 
along the crypt-villus axis, with the highest level of Wnt pathway activation occurring at 
the base of the intestinal crypts where the ISC population resides (Spit et al., 2018). The 
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ISC population remains in close contact to stromal tissue capable of providing an 
abundance of Wnt factors (Spit et al., 2018). Subsequently, when a Wnt ligand binds to its 
receptor complex containing Frizzled (FZ)/low-density lipoprotein (LDL) receptor-related 
protein (LRP), a signal is transduced to intracellular proteins that stimulates interaction 
between Dishevelled (Dsh) and Axin (Spit et al., 2018). This prevents the breakdown of β-
catenin and results in an accumulation of β-catenin in the cytoplasm and nucleus. β-catenin 
is then able to interact with a member of the lymphoid enhancer-binding factor 1 or T cell-
specific transcription factor (LEF/TCF) to enhance transcription of Wnt target genes (Spit 
et al., 2018).  
 
A variety of Wnt target genes function to enhance cell proliferation, migration and 
adhesion processes that are essential for intestinal and colonic epithelium homeostasis. 
Thus, the expression of Wnt target genes increases the proportion of stem cells (Spit et al., 
2018). As cells differentiate and migrate up the crypt-villus axis towards the lumen of the 
intestine, they lose their proximity to Wnt factors. In the absence of Wnt, a β-catenin 
destruction complex is formed preventing the downstream activation of Wnt target genes 
(Spit et al., 2018). Briefly, the intracellular proteins adenomatous polyposis coli (APC) and 
Axin are phosphorylated by glycogen synthase kinase-3 (GSK3), resulting in the 
breakdown of β-catenin (Spit et al., 2018). Subsequently, this decrease in Wnt signaling is 
thought to drive differentiation of the intestinal and colonic epithelium. Interestingly, 
conditional homozygous deletion of β-catenin in mice results in increased apoptosis, 
catastrophic destruction of crypts, reduced numbers of goblet cells and detachment of entire 
sheets of enterocytes (Sansom et al., 2004). These results highlight the important role of 
Wnt in maintaining the ISC compartment.  
 
Notch  
Similar to Wnt signaling, Notch also plays a role in maintaining the undifferentiated and 
proliferative stem cell compartment at the base of the crypt (Van der Fliers and Clevers, 
2009). This is supported by the high levels of Notch ligands found at the base of the crypt 
compared to the rest of the crypt-villus axis (Spit et al., 2018). In contrast to the Wnt 
pathway, Notch signaling can only occur via direct cell-to-cell contact of adjacent cells 
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(Spit et al., 2018). When Notch ligands (such as Jagged or Delta) interact with the Notch 
receptor, two proteolytic cleavage events are initiated (Spit et al., 2018). Firstly, tumour 
necrosis factor-α-converting enzyme (TACE), cleaves the extracellular domain of the 
Notch receptor (Spit et al., 2018). Then a second cleavage event takes place, which frees 
the Notch intracellular domain (NICD), enabling it to enter the nucleus (Spit et al., 2018). 
Once NICD enters the nucleus, it is able to activate the transcription factor CSL, resulting 
in the expression of Notch target genes (Spit et al., 2018). Similar to Wnt, Notch target 
genes influence apoptosis, proliferation, spatial patterning and cell fate determination 
(Artavanis-Tsakanoas et al., 1999). Inhibition of Notch signaling in mice results in a 
decrease of epithelial stemness and an increase in the goblet cell population (Sikander et 
al., 2010). This reinforces Notch’s role in maintaining the ISC compartment.  
 
TGFβ/BMP 
In contrast to Wnt and Notch signaling, the TGFβ/BMP signaling pathway is a negative 
regulator of intestinal stem cell renewal (He et al., 2004; Spit et al., 2018). In this role, the 
expression of TGFβ is concentrated at the villus tip where cells are differentiated and not 
proliferating (Spit et al., 2018). TGFβ and BMP pathways are activated in a similar manner: 
a ligand binds to the membrane-bound type II receptor that enables the type II receptor to 
dimerize with type I receptors and phosphorylate its cytoplasmic domain (Spit et al., 2018). 
Upon phosphorylation, type I receptors recruit and phosphorylate SMAD2/3 (TGFβ), or 
SMAD1/5/8 (BMP) proteins (Spit et al., 2018). Once phosphorylated these complexes are 
referred to as receptor regulated SMADS (R-SMADS) (Spit et al., 2018). To enable 
translocation into the nucleus, R-SMADS dissociate from the receptor and form a complex 
with SMAD4 (Spit et al., 2018). Once in the nucleus, SMAD4 interacts with regulatory 
proteins to activate transcription factors and downstream TGFβ/BMP genes (Spit et al., 
2018). The target genes of the TGFβ/BMP pathways are most commonly associated with 
inhibition of cellular growth and proliferation. Interestingly, inhibition of TGFβ/BMP 
signaling in mice increases the proportion of stem and progenitor cell populations, 
eventually leading to cancer (He et al., 2004). These findings highlight the inhibitory 
function of this pathway under homeostatic conditions and explains the ability of 






Hedgehog signaling has been found to primarily regulate the intestinal mesenchyme. 
However, it plays an important role as an indirect regulator of BMP and Wnt signaling 
(Kaestner et al., 1997; Spit et al., 2018). The hedgehog pathway is controlled by two 
transmembrane proteins known as Patched and Smoothened. When a ligand (Sonic 
Hedgehog (Shh), Indian Hedgehog (Ihh) or Desert hedgehog (Dhh)) binds to Patched, 
Smoothened inhibition is prevented, allowing for active Smoothened to prevent 
phosphorylation and degradation of Gli2/3 (Spit et al., 2018). Subsequently, Gli2/3 is able 
to enter the nucleus and act as a transcription factor for Hedgehog target genes. In 
particular, one important target gene of the Hedgehog pathway is FoxL1. FoxL1 has been 
shown to regulate BMP and Wnt signaling (Kaestner et al. 1997). Interestingly, FoxL1 
deficit results in increased intestinal epithelial proliferation and distorted crypt architecture 
(Kaestner et al. 1997). More recently, Kosinski and colleagues demonstrated a similar 
effect is caused by the loss of the Hedgehog ligand Ihh in the intestinal epithelium, 
manifesting as increased proliferation and expansion of the ISC compartment (Kosinski et 
al., 2010). The Hedgehog pathway also indirectly affects the ISC compartment through 
modulation of the adjacent mesenchymal tissue that makes up the supportive structure of 
the crypts (Kosinski et al., 2010). When Ihh was depleted, the mesenchymal architecture 
was disrupted and the extracellular matrix deteriorated. This lead to a loss of crypt 
architecture and an increase in the ISC population, highlighting the important link between 





Figure 6 | The four main signaling pathways involved in intestinal homeostasis. From 
left to right: WNT, Notch, TGFB/BMP and hedgehog signaling. These pathways all control 
the expression of genes associated with homeostatic processes such as proliferation, 
apoptosis, differentiation, growth and migration This figure was originally published in 
Current molecular medicine. Radtke, F., Clevers, H. & Riccio, O. From gut homeostasis 
to cancer. 2006; 6(3), 275-289. Modified figure shown here is different from the original 






1.2 Colorectal Cancer  
Colorectal cancer (CRC) is one of the most common cancers worldwide, with over 1.2 
million new cases diagnosed each year (Zeuner et al., 2014). In Canada, CRC is highly 
prevalent with an estimated 27,000 Canadians diagnosed in 2017 (Bromfield et al., 2017). 
Although aggressive treatment options such as surgery, radiation and chemotherapy are 
available, approximately 30-50% of patients will develop therapy-resistant CRC (TR-
CRC) leading to recurrent disease (Ragnahammar et al., 2001; O’Connell et al., 2008). 
Unfortunately, when TR-CRC is treated unsuccessfully, recurrent tumours that arise are 
often much more aggressive than primary tumours, resulting in poor survival rates 
(O’Connell et al., 2008). Other factors that have been found to impact patient survival 
include detection of CRC in advanced stages as well as high recurrence rates and tendency 
to metastasize. Due to this, CRC remains the second and third leading cause of death in 
men and women, respectively (Bromfield et al., 2017).  
 
By etiology, human CRC can be classified as inherited, colitis-associated, or sporadic. 
Inherited CRC can be categorized into: familial, hereditary nonpolyposis, familial 
adenomatous polyposis (FAP) and rare CRC syndromes. Familial CRC accounts for 10-
30% of all CRC cases and is defined by family history of non-syndromic CRC (Figure 7) 
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(Jasperson et al., 2010).  It is caused by an accumulation of mutations in intestinal epithelial 
cells and progresses through a well-characterized sequence (described in section 1.2.1) 
(Jasperson et al., 2010). Hereditary nonpolyposis CRC (HNPCC) or Lynch syndrome 
accounts for 5% of all CRC cases (Jasperson et al., 2010). It is an autosomal dominant 
condition that is caused by mutations in genes involved in the DNA mismatch repair 
pathway including MSH2, MLH1 and MSH6 (Jasperson et al., 2010). Familial 
adenomatous polyposis (FAP) accounts for 5% of all CRC cases and is caused by a 
germline mutation in the adenomatous polyposis coli gene (APC) (Jasperson et al., 2010). 
A subset of inherited CRCs is very rare and accounts for 0.1% of all cases. These include 
leiomyosarcomas, colorectal lymphomas, neuroendocrine tumours, as well as 
gastrointestinal stromal tumours (GISTs) (Jasperson et al., 2010). Colitis-associated CRC 
(CA-CRC) arises from areas of active colonic inflammation caused by inflammatory bowel 
disease (IBD) and accounts for 2% of all CRC cases (Van Der Kraak et al., 2015). It is 
caused by an accumulation of mutations in intestinal epithelial cells and progresses through 
a well-characterized inflammation to dysplasia to carcinoma sequence (described in section 
1.2.1) (Van Der Kraak et al., 2015).  Lastly, the majority of colorectal cancer cases are 
considered sporadic (~80%). However, the etiology of sporadic CRC remains elusive. In 
addition to hereditary- or disease-related aspects, a likely contributing factor to the 
development of CRC may be a number of lifestyle factors including: obesity, physical 




                                           
Figure 7 | Etiology of colorectal cancer. The etiology of human CRC can be classified as 
rare CRC syndromes (0.1%), colitis-related (2%), familial adenomatous polyposis (5%), 
Hereditary nonpolyposis (5%), familial (10-30%) or sporadic (65-85%).  
 
1.2.1  A model of colorectal carcinogenesis  
Early observations in human cancers and animal models reported that a successive 
accumulation of multiple genetic mutations is necessary to convert a normal human cell 
into a cancer cell (Foulds, 1954; Nowell, 1976). Following these initial observations, 
Fearon and Vogelstein proposed a model of colorectal carcinogenesis based on studies of 
the frequency of gene mutations at various stages of progression in human tumours (Fearon 
and Vogelstein, 1990). In this model, CRC development is a multistep process, whereby a 
series of genetic mutations leads to progression from the normal intestinal epithelium to 
dysplastic tissue to benign adenomas through to metastatic carcinoma (Figure 8). The 
initial step in colorectal carcinogenesis involves loss of function of APC resulting in 
constitutive activation of the Wnt-pathway and formation of a benign lesion (Fearon and 
Vogelstein, 1990). This is followed by an activating mutation in the small GTPase KRAS 
and subsequent inactivation of SMAD2/4 in adenomas and early carcinomas, respectively 
(Fearon and Vogelstein, 1990). Lastly, inactivating mutation in p53 lead to invasion and 
metastatic lesions (Fearon and Vogelstein, 1990) (Figure 8). Initial research on invasive 
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carcinomas from familial and colitis-associated CRC showed a similar genetic pattern of 
acquired mutations in APC, KRAS, SMAD2/4 and p53. This led to the assumption that 
genes important in the initiation and progression of familial CRC were also important in 
CA-CRC. Although the accumulated mutations were similar, the timing of these genetic 
mutations was found to vary greatly between familial and CA-CRC. In CA-CRC, the order 
of progression is reversed, whereby the initiating mutation tends to occur in p53, followed 
by SMAD2/4, KRAS and lastly APC (Van Der Kraak et al., 2015). Interestingly, the 
frequency of APC mutation in high grade dysplasia is also reduced (27.5%) compared to 
non-CA-CRC adenomas (50%) (Foersch et al., 2014). Thus highlighting the genetic 
differences in colorectal carcinogenesis between familial and colitis associated colorectal 
cancer.  
 
Figure 8| Model of colorectal carcinogenesis as proposed by Fearon and Vogelstein. 
Progression from normal epithelium to colorectal cancer requires an accumulation of 
mutations in particular genes that affect the balance between proliferation and apoptosis. 
The steps shown above occur during the development of sporadic colorectal cancer in 
normal colonic epithelium. However, not all colorectal tumours exhibit all the mutations 
shown in the above figure. Part of this figure was originally published in Nature. 
Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis and cancer of the 
intestine. 2014; 14(7), 468-480 and Nature reviews cancer. Davies, R. J., Miller, R., & 
Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. 2005; 
5(3), 199. Modified figure shown here is different from the original and is being included 





1.2.2 Cell of origin theory  
In colorectal cancer research, two theories about the cell of origin exist: the bottom-up and 
top-down model.  The bottom-up model proposes that stem cells are the cell of origin; i.e. 
stem cells acquire the initial mutations necessary for malignant conversion (Visvader, 
2011). Evidence for the malignant conversion of stem cells has been demonstrated using 
mouse models that allow for the induction of specific mutations in ISCs. In 2009, Barker 
et al. found that deleting the APC tumour suppressor gene in Lgr5-expressing CBC stem 
cells lead to rapid adenoma formation throughout the small intestine and colon (Barker et 
al., 2009). Further studies also demonstrated rapid adenoma formation upon aberrant Wnt 
activation in BMI1+ and K19+ cells, supporting the bottom-up model as transformation 
was initiated in a stem cell at the bottom of the crypt (Preston, Wong et al. 2003). In 
contrast, the top-down model opposes the unidirectional development of tumours from 
stem cells. In this model, transformation is initiated in a differentiated cell that spreads 
laterally, thus initiating tumour growth from the top down. Recently, it was demonstrated 
that loss of APC in a differentiated cell population followed by aberrant activation of 
nuclear factor-κB (NF-κB) through intestinal inflammation or KRAS mutation, leads to 
transformation of these cells (Schwitalla et al. 2013; Asfaha et al. 2015). However, APC 
inactivation alone was not sufficient to initiate tumorigenesis. This suggests that additional 
signals are required for malignant conversion of differentiated cells in the top-down model 
of carcinogenesis.  
1.2.3 Wnt signaling in cancer  
Wnt target genes play a key role in a number of regulatory processes associated with 
tumorigenesis, such as cell proliferation and adhesion (Staal et al., 2004). As such, 
abnormalities in the Wnt pathway are closely associated with cancer including CRC (Bienz 
and Clevers, 2000; Polakis, 2000). This important role of Wnt pathway in CRC was 
highlighted by the detection of truncating mutations in the tumour suppressor gene APC in 
1989 (Ashton-Rickardt et al., 1989). APC is an important negative regulator of the Wnt 
pathway and mutations in this gene often initiate the formation of CRC, as loss of APC 
occurs early on in carcinogenesis for sporadic and hereditary familial adenomatous 
polyposis (FAP) tumours (Ashton-Rickardt et al., 1989; Groden et al., 1991; Kinzler et al., 
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1991).  Moreover, it was found that mutations that result in activated Wnt signaling occur 
in about 80% of sporadic CRCs (Powell et al., 1992). Ultimately, loss of APC function 
prevents phosphorylation and degradation of β-Catenin (Miyaki et al., 1994). This leads to 
the accumulation and subsequent translocation of β-Catenin to the nucleus, driving 
uncontrolled LEF/TCF-mediated gene transcription (Polakis, 1999). As outlined in section 
1.1.4, target genes of LEF/TCF transcription are associated with the “stem cell signature” 
and enhance cell proliferation, migration and adhesion processes (Sansom et al., 2004; 
Gregorieff and Clevers, 2005; Van der Flier et al., 2007). Therefore, activation of Wnt 
signaling drives tumorigenic processes.  
1.2.4  Mouse models of colorectal cancer  
Mouse models addressing different CRC subtypes have been developed over several 
decades to closely approximate the molecular, histopathological, and etiological 
characteristics observed in human CRC. Moreover, many of the molecular interactions and 
signaling strategies in the Wnt pathway are highly conserved between humans and mice 
enhancing mouse models as faithful models of human CRC.  
 
Mouse models of FAP 
The APCmin mouse model was first reported in 1990 as a model of FAP after a mouse 
with multiple intestinal neoplasia was discovered from an ethyl-N-nitrosourea chemical 
mutagenesis screen (Moser et al. 1990). Sequencing of this mouse, revealed it carried a 
truncation mutation of one allele of APC (Moser et al. 1990). Therefore, the mouse line 
was termed APCmin (multiple intestinal neoplasia). Interestingly, one allele of the APC 
gene remains intact and capable of maintaining a functional β-catenin destruction complex 
to prevent tumourigenesis. However, sporadic loss of the functional allele over time leads 
to the activation of β-catenin and expression of Wnt target genes. The most common cause 
of loss of heterozygosity of APC is mitotic nondisjunction of chromosome 18 where the 
APC gene is located (Dalton et al., 2007; Powell et al., 1992). 
 
The APCmin model recapitulates many aspects of FAP. Tumourigenesis in this model is 
driven by truncation mutations in the APC gene. APCmin tumours also share 
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histopathological characteristics with early human CRC (Zasadil et al., 2016). However, 
there are slight discrepancies between human FAP and the APCmin mouse model. Firstly, 
APCmin mice primarily develop tumours in the small intestine, in contrast to humans 
where polyps are primarily observed in the colon (Cunningham et al., 2010; Kettunen et 
al., 2003). The reasons for this are not fully understood. Secondly, it is not uncommon to 
see hundreds of tumours lining the colonic epithelium in human FAP (Cunningham et al., 
2010). However, APCmin model shows approximately 30 polyps in the ileum of the small 
intestine (Moser et al. 1990). Over time, human FAP tumours may metastasize, however, 
this phenomenon is rarely observed in APCmin mice. APCmin tumours may occasionally 
invade the underlying mucosa and muscularis externa but they do not metastasize. A 
possible explanation for this may be the relatively short lifespan of these mice (30 weeks), 
which does not allow sufficient time for more advanced stages of the disease to develop. 




Cre-lox mouse models of CRC  
Although the APCmin model is useful for studying intestinal tumourigenesis, it has limited 
utility when investigating the earliest stages of CRC. Initial onset of CRC is caused by 
inactivation of both alleles of APC, while in the APCmin mouse model, the time that 
heterozygosity is lost is unknown (Gryfe et al. 1997). Therefore, a model in which both 
alleles of APC could be deleted at specific time points was created using a conditional Cre-
loxP recombination system (Evans et al., 2016). The Cre-loxP system recombines DNA 
between any two loxP sites in the same orientation when Cre-recombinase is expressed by 
a tissue-specific promoter (Evans et al., 2016). For example, to direct conditional APC loss 
in a K19-expressing cell, tamoxifen mediated cre-expression would be directed from a 
tissue specific promoter K19 to an essential exon (exon 14) of APC flanked by loxP sites. 
As the K19-CreERT transgene encodes a cre-recombinase estrogen-receptor (ER) linked 
protein, it will remain inactive until tamoxifen is present and binds to the ER, freeing the 
Cre-recombinase and activating the enzyme to cut the loxP sites surrounding exon 14 of 
APC. This results in loss of functional APC protein in K19 expressing cells and 
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subsequently tissue specific/conditional knockout of APC with tamoxifen induction. An 
advantage to using this model is the ability to drive expression of Cre-recombinase from 
different tissue-specific promoters, thereby driving recombination of a number of genes in 
different tissues or cellular compartments. Accordingly, this model has enabled the initial 
stages of intestinal tumorigenesis to be studied in detail. In particular, this model was used 
to identify Lgr5 as a cellular origin of CRC, as mentioned in section 1.2.2.  
 
Besides altering the function of genes in a specific tissue or cell compartment, Cre-Lox 
technology has enabled cell lineage tracing to determine the genetic origin of a tumour. For 
example, LacZ reporter gene crossed to a K19-Cre mouse will express B-galactosidase 
when recombined (Asfaha et al., 2015). Additionally, daughter cells of the recombined 
cells will inherit the genetic marker, which can then be stained using X-gal. This allows 
for visualization of K19 cells and progeny when crossed to a tumour model. This model 
was used to identify K19 as a cellular origin of CRC, as detailed in section 1.2.2. 
Furthermore, the same principle of genetic lineage tracing has also been used in the non-
mutated intestine to identify ISCs as described in section 1.1.3.  
 
Mouse models of colitis-associated CRC  
The AOM/DSS model is a well-established animal model of colitis-associated cancer, 
whereby colorectal cancer is induced chemically. In this model, a single intraperitoneal 
(i.p.) injection of a genotoxic colonic carcinogen, azoxymethane (AOM) (10 mg/kg body 
weight) and exposure to a non-genotoxic inflammatory agent, dextran sodium sulfate 
(DSS) (2.5%) in the drinking water for five days results in the development of multiple 
colonic tumours in approximately 9-12 weeks, with mice becoming moribund at 20 weeks 
with an average of 7 tumours (Rosenberg, 2008). DSS is toxic to the epithelial lining of the 
colon and produces severe colitis similar to what is seen in patients with inflammatory 
bowel disease (IBD) (Rosenberg, 2008). The pathogenesis of tumours induced in mice 
exposed to AOM/DSS is similar to that observed in human colitis-associated cancer. For 
instance, tumours are frequently found in the distal part of the colon, which is also the 
predominant location of colitis-associated cancer in humans (Rosenberg, 2008). Likewise, 
AOM/DSS tumours have been reported to share molecular features with human CRC, such 
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as dysregulation of β-catenin-signaling pathway (Takahashi et al., 1998; Takahashi et al., 
2000) and mutations in K-Ras (Takahashi and Wakabayashi, 2004). However, they rarely 
display mutations in p53 or Smad4 and detailed molecular mechanisms of the AOM/DSS 
model are still very limited (Rosenberg, 2008). Regardless, the AOM/DSS model is 






1.3 Cancer Stem Cells  
 
The cellular composition of CRCs maintains a high degree of similarity to normal intestinal 
tissue, with the appearance of glandular structures, although structurally disorganized in 
comparison to normal tissue (Medema and Vermeulen, 2011). Moreover, a variety of 
differentiated cell types are found in CRCs that are also present in the normal intestinal 
tissue (Blank et al., 1994; Grabowski et al., 2004; Marsh et al., 1993; Pierce et al., 1977; 
West et al., 1988). These findings can also be interpreted to suggest that like their normal 
tissue of origin, tumour cells are organized into a hierarchy of potency. Support for this 
interpretation was enforced by the discovery of stem cell-like cancer cells that expressed 
ISC markers (see section 1.1.3), which were multipotent and capable of self-renewal 
(Ricci-Vitiani et al., 1988; O’Brien et al., 2007; Dalebra et al., 2011).  These findings 
support the cancer stem cell (CSC) hypothesis, which posits only a small subpopulation of 
cancer cells are capable of driving tumour growth and progression. Furthermore, it is 
postulated that therapy-resistant CRC arises from CSCs capable of evading treatment and 
persisting in tumours to cause relapse (Sarkar et al., 2009; Yu et al., 2012). Therefore, 
CSCs represent a novel therapeutic target for the treatment and/or prevention of tumour 
progression. However, there are still many uncertainties regarding their identification, 
functional properties and importance, which are outlined below (Medema, 2013). 
1.3.1  History and Identification  
CSCs were first identified nearly 20 years ago in acute myeloid leukemia through serial 
transplantation assays (Lapidor et al., 1994). In this assay, subpopulations of tumour cells 
expressing identified surface markers are sorted via FACS, transplanted into 
immunocompromised mice and evaluated for tumour formation (Figure 9). Using this 
experimental technique, Bonnet & colleagues were able to identify a small subpopulation 
of CD34+/CD38- leukemic cells capable of establishing human leukemia (Bonnet et al., 
1997). Interestingly, the other cell populations failed to form tumours. These results 
indicated that CD34+/CD38- cell population labelled cancer initiating cells or CSCs 
(Bonnet et al., 1997). Accordingly, serial transplantation assays using xenografts have 
become the gold standard to define CSCs, and many CSCs have been identified in several 
solid tumour types including: medulloblastoma/glioblastoma (Singh et al., 2004), breast 
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(Al-Hajj et al., 2003), pancreatic (Fredebohm et al., 2012), prostate (Collins et al., 2005), 
and colorectal (Ricci-Vitiani et al., 2007; O’Brien et al., 2007) cancers, among many 
others. However, there are many limitations with this assay when applied to epithelial 
cancers, such as colorectal cancers (Nguyen et al., 2012; Zeuner et al., 2014; Plaks et al., 
2015). This assay has identified the existence of CSCs in CRC but these cells often show 
poor engraftment, even after enrichment for CSC markers (Ricci-Vitiani et al., 2012; 
O’brien et al., 2007; Kobayashi et al., 2012; Kemper et al., 2012). This may largely be due 
to sorted epithelial cells undergoing anoikis during detachment from the tissue (Fuji et al., 
2017). Moreover, epithelial stem cells are passively regulated by their microenvironment 
(niche), suggesting that repopulation efficiency may reflect the robustness or fitness of the 
transplanted cells into the recipient niche rather than stemness (Fuji et al., 2017). 
Interestingly, this phenomenon was observed in serial transplantation assays performed 
with melanoma cells. Quintana et al. found that the tumorigenic capacity of transplanted 
melanoma cells changed with the level of immune deficiency of host animals (Quintana et 
al. 2008).  
To circumvent the drawbacks of serial transplantation assays, lineage tracing of genetically 
marked cells has been used to identify colorectal CSCs in genetically traceable mouse 
tumour models (Driessens et al., 2012; Schepers et al., 2011; Asfaha et al., 2015). The first 
evidence to support the existence of CSCs using this method, was demonstrated in three 
independent lineage tracing studies of brain (Chen Li et al., 2012), skin (Driessens et al., 
2012) and intestinal (Schepers et al., 2011) cancers. In regards to colorectal cancer, 
Schepers et al. employed the confetti mouse model to initiate “lineage retracing” in 
intestinal adenomas. They demonstrated that a small subpopulation (5-10%) of tumour 
cells was labelled by the ISC marker Lgr5 which fueled the growth of established intestinal 
adenomas and displayed multi-lineage differentiation potential indicative of CSC activity. 
However, it is important to note that sorted Lgr5+ intestinal tumour cells have not been 




Figure 9 | Identification of cancer stem cells. Serial transplantation assays allow for the 
identification of cancer stem cell populations. Patient tumours are dissociated into single 
cell populations and injected into immunocompromised mice to assess the formation of 
tumours. Only the injection of CSCs will yield tumours, whereas injection of tumour cells 
that lack cancer stem cell properties will not result in tumour formation or growth. To 
determine whether the cancer stem cell population is capable of self-renewal, xenografted 
tumours are removed and put through this process again to assess tumour formation/growth 
in secondary recipients. Only the cancer stem cell population will possess long-term self-
renewal capacity and it will regenerate the tumour, whereas injection of non-CSCs will not 
re-initiate tumour growth.  
1.3.2 Colorectal cancer stem cell markers  
Identification of colorectal CSCs relies heavily on the expression of cell surface or ISC 
markers. As such, many CSC markers have been proposed and their ability to robustly 
identify the colorectal CSC population is discussed below.  
1.3.3 Cell surface markers 
A number of cell surface markers have been proposed to identify colorectal CSCs including 
CD133 (Ricci-Vitiani et al., 2007; O’Brien et al., 2007), CD44 (Chu et al., 2009) and 
ALDH1 (Huang et al., 2009). Using serial transplantation assays, these markers were 
identified on the basis that enriched populations initiate tumours in xenograft models, 
whereas depleted populations did not. However, many of the CSC markers identified from 
these assays were chosen because the proteins were expressed in colorectal cancer tumours. 
Unlike this reasoning, the original studies conducted on leukemic CSCs relied heavily on 
the understanding of stem-progenitor hierarchies in the healthy bone marrow to establish 
relevant highly reliable CSC markers (Lapidot et al., 1994; Bonnet et al. 1997). However, 
few studies have employed this methodology. In fact, one study implicated CD44 as a CSC 
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in breast cancer despite the lack of CD44 in normal breast epithelial stem-progenitor 
hierarchies (Al-Hajj et al., 2003). This suggests that CD44 was incorrectly chosen for its 
differential expression in breast tumours. In addition to CD44, CD133 or prominin 1 has 
been suggested as a CSC marker in a variety of cancers, which shares expression with its 
normal stem-progenitor tissue counterparts. Although recently, it was revealed that CD133 
is widely expressed in many tissues (Shmelkov et al., 2008). Therefore, there is 
considerable disagreement over the validity and usefulness of this CSC marker. Initially, 
CD133 was proposed as a useful CSC marker in CRC (O’Brien et al., 2007; Ricci-Vitiani 
et al., 2007), as well as brain cancers (Singh et al., 2004; Bao et al., 2006). However, these 
findings were later refuted in subsequent studies (Dalebra et al., 2007; Shmelkov et al., 
2008; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2010; Chen et al. 2010). These 
studies highlight the need for selection of CSCs that are relevant and specific to the 
underlying stem cell biology of normal tissues from which the cancer originates.  
The following sections outline a select few cell surface proteins that may function as CSC 
markers in CRC.  
CD133 
CD133 or prominin-1 expression has been used to identify CSCs in a number of different 
cancers including medulloblastoma/glioblastoma (Singh et al., 2004), prostate (Collins et 
al., 2005; Richardson et al., 2004), pancreatic (Hermann et al., 2007) and colorectal cancers 
(Ricci-Vitiani et al., 2007; O’Brien et al., 2007). CD133 is a 120kDa five-transmembrane 
cell surface protein that has been reported to affect many cellular processes including 
stemness, tumourigenesis, chemo/radioresistance, metabolism, autophagy and apoptosis 
(Li, 2013). In the colon, CD133 was the first CSC marker used. It was found that 1000-
3000 CD133+ cells were capable of initiating tumours in immunodeficient mice (Ricci-
Vitiani et al. 2007; O’Brien et al. 2007). However, recent studies have suggested that 
CD133 may not be a robust CSC marker. Importantly, it was found that when the CD133 
negative population was transplanted into NOD/SCID mice, tumour formation was 
initiated (Shmelkov et al. 2008). Moreover, knockdown of CD133 does not affect colony 
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formation efficiency or tumorigenic capacity, highlighting the need for a more pertinent 
CSC marker in CRC (Du et al., 2008). 
CD44 
Another commonly employed CSC marker is CD44. CD44 has been identified as a CSC 
marker in breast (Al-Hajj et al., 2003; Pham et al., 2011), prostate (Collins et al., 2005), 
gastric (Yoon et al., 2014) and colorectal (Du et al., 2008; Dalebra et al., 2007) cancer. 
Functionally, CD44 is a receptor for hyaluronic acid and plays a role in normal cell-cell 
adhesion as well as proliferation, motility, adhesion and cell survival in cancer (Keysar and 
Jimeno, 2010; Afify et al., 2009; Marharba and Zoeller, 2004). In comparison to normal 
tissue, CD44 has been found to be upregulated in colorectal cancer tissue. Moreover, 
CD44+ cells isolated from primary colorectal tumours demonstrate increased tumorigenic 
capacity, with as few as 100 CD44+ cells leading to tumour initiation in mice (Du et al., 
2008; Dalebra et al., 2007). In contrast to CD133, CD44+ cells demonstrate enhanced 
colony formation efficiency indicating self-renewal (Chu et al., 2009; Du et al. 2008; Wang 
et al., 2012). Furthermore, CD44+ cells formed heterogeneous tumours containing CD44- 
cells in vivo, demonstrating the ability of this population to differentiate into other cancer 
cell types (Chu et al., 2009). Importantly, when CD44 was knocked down in primary 
tumour samples, colony formation and tumourigencity was inhibited. Thus, highlighting 
the role of CD44 as a functional marker of colorectal CSCs.  
ALDH1 
In addition to CD133 and CD44, aldehyde dehydrogenase 1 (ALDH1) is a commonly used 
marker of CSCs. It has been detected in numerous cancers including ovarian (Deng et al., 
2010), bladder (Su et al., 2010) and colorectal (Huang et al., 2009). Functionally, ALDH1 
is a member of the ALDH gene family, which catalyzes the oxidation of acetaldehydes and 
retinal (retinaldehyde) (Tomita et al., 2016), and it contributes to a variety of cellular 
processes through activation of retinoid signaling. The expression of ALDH1 is detectable 
by antibody based methods or enzymatic assay. However, the enzymatic assay lacks 
specificity for different ALDH isoforms. The activity of ALDH1 is elevated in normal 
stem/progenitor cells including ISCs (Dalebra et al., 2007). In several studies, when cancer 
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cells were sorted based on ALDH1 activity, a tumour initiating population was revealed 
(Tanei et al., 2009; Su et a.l, 2010; Kim et al., 2011; Sullivan et al., 2010). These results 
suggest that high activity or expression of ALDH1 is a useful method for identifying and 
isolating CSC populations in a variety of cancer types (Tanei et al., 2009; Su et al., 2010; 
Kim et al., 2011;Huang et al., 2009).  
Known intestinal stem cell markers 
Lgr5 
In 2012, Clevers et al. provided the first in vivo validation of a colorectal CSCs using a 
novel transgenic mouse model, which allowed them to visualize lineage re-tracing in 
established tumours (Schepers et al., 2011). This work stemmed from earlier genetic fate 
mapping studies in the normal intestine. In this study, they identified Lgr5-expressing crypt 
base columnar cells as a stem cell population able to give rise to all intestinal cell types 
(Barker et al., 2007). Interestingly, upon ablation of Lgr5+ cells in the normal intestine, 
other stem cells have been shown to regenerate Lgr5+ cells and their progeny (Tian et al., 
2011). This demonstrates the presence of a heterogeneous pool of stem cell populations in 
the normal intestinal epithelium. Though it is not known whether CSCs represent a 
heterogeneous pool encompassing different cell types in a much like the normal intestinal 
epithelium.  
Proposed intestinal stem cell markers 
 
K19  
Our laboratory recently identified Keratin-19 (K19) as a potential CSC marker. 
Cytokeratins are a multigene family of intermediate filaments, critical in the maintenance 
of the cytoskeleton but expressed in different lineages in the epithelium (Moll et al., 1982). 
Keratin-19 is the smallest known acid keratin (approximately 40kDa) and is epithelial-
specific, found in a broad range of epithelial tissues (Lapouge et al., 2011). In the small 
intestine and colon, our laboratory identified K19+ cells as radioresistant tissue stem cells 
capable of giving rise to Lgr5+ cells (Asfaha et al., 2015). Interestingly, K19 is also 
amplified in many solid tumours making it an ideal candidate marker for CSCs (Lapouge 
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et al., 2011). Our preliminary data (not included here) further demonstrated that K19 
identifies CSCs in established colonic tumours.  
1.3.4 Targeting cancer stem cells 
CSCs are believed to play an important role in the maintenance of tumour growth, 
metastasis, as well as therapy resistance. Therefore, from a therapeutic standpoint, the 
elimination of CSCs is necessary to eliminate the tumours. However, treatments that are 
currently used in CRC are aimed at targeting rapidly dividing cells that make up the bulk 
of the tumour via chemotherapy or radiation. Unfortunately, these treatments are often 
unsuccessful at targeting slow-cycling CSCs. As a result, CSCs are thought to evade 
treatment, causing relapse of disease and the emergence of therapy-resistant CRC (Figure 
10). This notion, has led to multiple studies targeting CSCs in CRC. Recently, Shimokawa 
et al and de Sousa e Melo et al investigated targeted ablation of Lgr5 expressing CSCs in 
two different models of colorectal cancer. Initially, both groups observed tumour 
regression, as one would expect to see if the source of cancer growth is being ablated. 
However, upon discontinuing ablation of Lgr5+ cells in established tumours, Lgr5+ cells 
reappeared and growth rapidly resumed (de Sousa e Melo et al., 2017; Shimokawa et al., 
2017). Moreover, targeted ablation of Lgr5+ cells using an antibody-directed 
chemotherapeutic in APCmin mouse model had no effect on tumour burden (Juntila et al., 
2015). This demonstrates that depending on the tumour model, the CSC pool might 
encompass different cell phenotypes and that elimination of Lgr5+ CSCs might alter 
tumour growth but may not eradicate the disease. This highlights the need to identify other 
CSC populations that may exist in CRCs.  
From what we know about the functional role of CSCs in CRC, it is evident that a method 
of targeting CSCs is necessary to eradicate disease. However, this presents a number of 
difficulties related to the stem cell niche and bona fide markers. It is likely that the tumour 
environment regulates CSCs, much like what is observed in the normal intestinal 
environment. However, it remains unknown whether the tumour initiating activity is 
inherent to CSCs. This has major implications in terms of targeting CSCs. If the latter is 
correct, simply ablating CSCs will likely have non-significant effect on tumour growth 
other stem cells in the environment may assume the role of CSCs. Secondly, a major 
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challenge in targeting CSCs remains the lack our understanding of definitive markers 
identifying CSCs. The markers that have been used to identify CSCs thus far are poor 
candidates for antibody-directed therapy, as they are broadly expressed in healthy tissue. 
Together these challenges highlight the need to increase our understanding of normal ISCs 
and CSCs, as well as the seemingly interconnected relationship between niche 
environments and CSC plasticity to develop effective therapeutic targets.  
 
 
Figure 10 | CSC-targeted therapy versus traditional cancer therapy. This figure was 
originally published online in Sigma-Aldrich. Cancer stem cells: new targets for cancer 
therapy [https://www.sigmaaldrich.com/technical-documents/articles/biofiles/the-cancer-
stem-cell.html]. Modified figure is being reproduced for educational purposes only and not 





1.4  Rationale  
 
Evidence in the normal intestinal epithelium reveals stem cell populations represent a 
heterogeneous pool encompassing different cell types in a dynamic equilibrium (Barker et 
al., 2007). For example, stem cell activity is observed at the base of intestinal crypts in 
rapidly dividing cells that express leucine-rich repeat-containing G protein-coupled 
receptor (Lgr5) (Tian et al., 2011). However, genetic ablation of Lgr5+ cells in vivo does 
not appear to drastically alter tissue homeostasis, suggesting that their loss can be 
compensated for by the recruitment of a different Lgr5 negative stem cell populations 
which are capable of regenerating Lgr5+ cells (Ricci-Vitiani et al., 2007; O’Brien et al., 
2007; Rizk et al., 2012; Moll et al., 1982). Our laboratory has identified Keratin-19 (K19) 
expressing cells as tissue stem cells at the apex of cellular hierarchy able to give rise to 
Lgr5+ cells (O’Brien et al., 2007). However, the extent to which these processes are 
paralleled in malignant tissues through CSC activity remains unclear. In 2012, Clevers and 
colleagues identified Lgr5 as a marker of colorectal CSC using a model of lineage re-
tracing in established tumours (Ricci-Vitiani et al., 2007). Based on the results and 
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implications of these studies, I aim to determine if K19 labels a cancer stem cell population 
in an in vivo model of colorectal cancer. 
1.4.1  Hypothesis 
I hypothesize that K19 will label a cancer stem cell population that is distinct from 
previously identified Lgr5+ cancer stem cells and contributes to colorectal tumour growth. 
1.4.2 Objectives  
1. Determine if K19 labels a cancer stem cell population in colorectal cancer 










Chapter 2  
MATERIALS AND METHODS 
2.1  Experimental Animals 
 
All animal care and experimental procedures were approved by the Canadian Council of 
Animal Care and the Animal Use Subcommittee of the University of Western Ontario. 
 
2.1.1           Animal husbandry 
Mice were housed in transparent plastic cages in a room with a 12h light/12 h dark cycle. 
The mice were fed standard laboratory chow (Lab Diet) and tap water ad libitum.    
2.1.2           Breeding 
All strains were generated on a C57BL/6 background. Mice were bred at approximately 6 
weeks of age. Pups were weaned at approximately 4 weeks old when feeding 
independently. Pups were sexed and separated at weaning, and ear-tagged for 
identification. At this time, small tail biopsies (3-4 mm) were collected for genotyping. 
2.1.3          Genetic mouse models 
A number of transgenic mouse models were utilized in this study (Table 1). The transgenes 
used contained exons of the gene of interest flanked with loxP sites, or insertion of human 
diphtheria toxin receptor to enable conditional deletion of genes, or cre-recombinase-





Table 1| Transgenic mouse models 
Model Type of 
transgene 
Expression Mutation Effect Reference 
K19-
CreERT2 
BAC Inducible Tamoxifen inducible CreERT2 fusion 
gene inserted into K19 gene coding 
region of K19 containing BAC clone 
(BAC RP-23-24N13). 
Label K19+ expressing cells and progeny 
when combined with a reporter gene under 





Knock-in Inducible Cre reporter allele with loxP flanked 
stop cassette preventing transcription 
of CAG promoter-driven red 
fluorescent protein variant (TdTomato) 
inserted into the Rosa 26 locus. 
Spatiotemporally label cells and progeny 
red when crossed to a cre recombinase gene 
under the control of a promoter of interest 




Knock-in Constitutive Exon 1 in the Lgr5 gene is linked in 
frame to eGFP and a human DTR 
cDNA, producing a fusion protein 
  
Expression of eGFP functions as a reporter 
for Lgr5 expression and diphtheria toxin 
receptor confers diphtheria toxin 
sensitivity to Lgr5+ expressing crypt base 
columnar cells. 




APCf/f Knock-in Inducible Exon 14 in the APC gene is flanked by 
loxP sites 
Ablation of APC functional protein when 
crossed to mice a cre recombinase gene 
under the control of a promoter of interest 





Constitutive Germline nonsense mutation at codon 
850 of APC 
Spontaneous loss of heterozygosity leads 
to tumour formation in small intestine and 
colon in ~6 months 






2.1.4          Mouse lines  
To address the aims of this thesis, a number of mouse lines were generated from the mouse 
models outlined in Table 1. The mouse lines generated were used to visualize progeny of 
K19 and ablate Lgr5 cells in various CRC models. The details of these mouse lines are 
outlined in Table 2. 
 
Table 2 | Mouse lines 
Mouse line Effect 
K19-CreERT;Rosa26-TdTomato Treatment with tamoxifen induces excision of the 
STOP codon preventing TdTomato expression in 
K19 expressing cells resulting in robust TdTomato 
fluorescence. When these mice are treated with 
AOM/DSS, this allows for lineage tracing of K19+ 
cells and progeny in tumours. 
K19-CreERT;Rosa26-
TdTomato;APCmin 
When crossed to APCmin mice which 
spontaneously form tumours, we are able to 
lineage trace K19 cells in tumours using a similar 
principle to the above mouse line. 
Lgr5-DTR-eGFP When these mice are treated with AOM/DSS, this 
mouse model allows for specific ablation of all 
Lgr5+ cells in tumours. 
Lgr5-DTR-eGFP; K19-CreERT;APCf/f Treatment with tamoxifen induces a loss of 
functional APC protein in K19 expressing cells, 
resulting in tumour formation. Additionally, with 
the presence of Lgr5-DTR, this allows for specific 




K19-CreERT2;APCf/f Treatment with tamoxifen induces a loss of 
functional APC protein in K19 expressing cells, 
resulting in tumour formation. 
 
2.1.5           Experimental design 
 
K19-CreERT;R26TdTomato;APCmin 
To induce cre-mediated lineage tracing of TdTomato in established adenomas, 3mg of 
tamoxifen in 200 μL corn oil was administered to 20 week-old mice by oral gavage (Figure 
11). Following tamoxifen induction of Cre recombinase in K19+ cells, TdTomato labelling 
was assessed by immunofluorescence microscopy. Mice were sacrificed at 24 hours, 10 
days and 4 weeks post-tamoxifen. Tissue sections were counterstained with DAPI (Fisher). 
 




To assess CSC properties of K19+ cells in vivo, I performed lineage tracing analysis of 
adenomas K19-CreERT;R26TdTomato mice treated with AOM/DSS mice. To induce cre-
mediated lineage tracing of TdTomato in established adenomas, 3mg tamoxifen (K19) in 
200 μL corn oil was administered to 15-week old mice by oral gavage (Figure 12). 
Following tamoxifen induction of Cre recombinase in K19+cells, TdTomato labelling was 
assessed as described above. 
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Figure 12 | Experimental protocol for K19-CreERT2;R26TdTom AOM/DSS mice 
Lgr5-DTR-eGFP AOM/DSS 
To examine the effect of Lgr5+ cancer stem cell ablation on tumour initiation and growth 
in vivo, I administered 500ng of diphtheria toxin 2x per week from week 3 post-AOM 
(Sigma) until the experimental endpoint at 20 weeks, to selectively ablate Lgr5+ cells in 
Lgr5-DTR-eGFP mice treated with AOM/DSS (Figure 13). Administration of DT (Sigma) 
from week 3 onwards ensured Lgr5+ cells are ablated for the duration of tumour initiation 
and growth. Therefore, cohorts of experimental (DT-treated) and control (saline- treated) 
mice (n > 10 per group) were compared with respect to tumour burden (number and size) 
and histology at 20 weeks. 
 
Figure 13 | Experimental protocol for Lgr5-DTR-eGFP AOM/DSS mice 
2.2   Genotyping of mice  
 
Polymerase chain reaction (PCR) was performed to genotype weaned mice using genomic 
DNA (gDNA) extracted from tail biopsy. Confirmatory genotyping was also performed at 
the time of death to ensure the mouse was assigned to the correct experimental cohort. 
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2.2.1           Nucleic acid isolation  
Tail samples were placed in 1.5 mL centrifuge tube and stored at 4°C until use. 75 L of 
tail lysis buffer (Appendix II) was added to tubes and incubated at 98°C for one hour. 
Samples were cooled on ice for 5 minutes and 75 L of neutralization buffer was added 
(Appendix II). Following neutralization, samples were centrifuged at 4000 rpm for 3 
minutes at 4°C and the supernatant was used for PCR. gDNA was stored at room 
temperature (RT) for short term use and at 4°C for long term storage. 
2.2.2           PCR protocol 
PCR was carried out in thin-wall 12-well strip tubes (Fisher). Two L of gDNA, extracted 
as described above, was added to each tube with 18 L of PCR mix (described in Table 3) 
containing the DNA polymerase (FroggaBio), H2O (FroggaBio), and gene-specific 
primers. One negative control (H2O only) and positive control tube was run with every 
PCR reaction. Primers were used as described from previous publications (Appendix III). 
The caps were placed firmly on tubes and the PCR reactions were on a thermocycler (Life 
Technologies, Verti PCR machine). PCR conditions and primers are listed in Appendix IV. 
 
Table 3 | Constituents of PCR mix 
 
Component 20 L reaction 
Taq polymerase (FroggaBio) 10 L 
Forward primer 0.5 L 
Reverse primer 0.5 L 
Template DNA 2 L 
Nuclease-free H2O (FroggaBio) 7 L 
 
2.2.3           Visualization of PCR products  
PCR products were visualized by gel electrophoresis. Agarose gels were made by 
dissolving 8 g of agarose (Fisher) in 400 mL TAE buffer [40mM Tris; 19mM Acetic Acid 
(Fisher)] in a conical flask by heating in a microwave until boiling. Ten L of ethidium 
bromide (Sigma) was added to the melted gel and agitated carefully to ensure even 
distribution without incorporating air bubbles into the gel. One hundred fifty mL of gel 
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solution was poured into each mold (Bio-Rad) and combs inserted to create wells. Once 
the gels were set, the combs were removed and they were placed into gel electrophoresis 
tanks and covered with TAE. 
 
Ten µL PCR product was added to each well of the agarose gel and run alongside a 
molecular weight ladder (Fisher). The gel was run at 140 V for approximately 30 minutes, 
and visualized using a GelDoc UV trans illuminator (Bio-Rad).  
2.3       AOM/DSS Administration 
To induce colonic tumours, K19-CreERT/R26TdTomato, Lgr5-DTR-eGFP and WT mice 
were subjected to a well-established, chemically-induced inflammation protocol (Wirtz et 
al., 2007; Tanaka, 2003). Mice (6-8 weeks old) were injected intraperitoneally (i.p.) with a 
single dose of AOM (with 10 mg/kg, (Sigma)) diluted in saline. After one week, 2.5% DSS 
(Gojira) was administered in the drinking water for 5 days, followed by regular drinking 
water. Throughout DSS administration, mice were assessed for health condition by using 
a scoring system. Mice were euthanized if endpoints were reached or 16-20 weeks post 
AOM administration. 
2.4    Tamoxifen Preparation and Administration 
Tamoxifen (Sigma) was dissolved in corn oil (Sigma) to a final concentration of 20 mg/mL. 
The sample was placed in a rotor and heated at 37°C until the tamoxifen was  completely 
dissolved. In order to induce Cre expression in Cre-ERT mice, tamoxifen was administered 
via oral gavage. For tamoxifen dosing of each mouse line, please refer to Table 4. 
 
Table 4 | Doses of tamoxifen used for each mouse line 








2.5    Diphtheria Toxin Preparation and Administration 
 
Diphtheria toxin stock solution was prepared from 1 mg of solid powder (Sigma). The 
powder was first dissolved in 1 mL of 0.9% saline. The solution was then diluted to a final 
concentration of 500 ng/200 µL and transferred to centrifuge tubes. Final prepared toxin 
solution was stored at -80°C and thawed directly before application. 
2.6    Tissue Preparation 
2.6.1           Tissue dissection  
Mice were euthanized in a CO2 chamber for 4-5 minutes, followed by cervical dislocation. 
Mice were sprayed with 70% ethanol and the skin and muscle of the abdomen cut through 
to open the abdominal cavity. The small intestine and colon were removed and flushed 
with PBS (Fisher). For organoid culture studies, 5-10 cm of the proximal small intestine 
and the entire colon was collected. For lineage tracing in AOM/DSS experiments only, the 
colon was collected. For APCmin lineage tracing experiments, both the small intestine and 
colon were collected. For Lgr5-DTR AOM/DSS experiments, small intestine and colon 
were collected. All tissues were collected into 4% paraformaldehyde (PFA; Santa Cruz) on 
ice. 
2.6.2           Tissue fixation  
For histological analysis, the organs were cut longitudinally, “Swiss rolled” (Moolenbeek 
and Ruitenberg 1981), inserted into embedding cassettes and fixed 6-8 hours in 4% 
paraformaldehyde in PBS at 4°C.  
2.6.3            Preparation of tissues 
Tissues were cryopreserved in 30% sucrose in PBS at 4°C for 48 hours. For subsequent 
histological analysis, tissues were embedded in Optimal Cutting Temperature (OCT) 
(Fisher) and stored at -80°C overnight before being cut to 5 µm slices with a microtome-
cryostat (Leica) at -21°C and picked up on glass slides (Fisher). Slides were stored at -




For long-term cohorts where an accurate tumour count was required, small and large 
intestines were flushed with cold 1 X PBS and opened longitudinally on filter paper 
(Fisher). Tumour number and volume (calculated as length x width x width) counts were 
performed and the gut was rolled using dissection tweezers and placed into cassettes and 
fixed as described above. 
2.7       Histology 
2.7.1           Hematoxylin & Eosin (H&E) staining 
For routine histological analysis, frozen slides were warmed to room temperature for 10 
minutes and rehydrated for two minutes in descending gradient of ethanol (100%, 95%, 
70% and 50%). The tissue slides were washed in ddH2O and stained for 7 minutes in a 
ready to use hematoxylin solution (Cedarlane). Residual stain was washed off in tap water. 
In order to stain eosinophilic structures and the cytoplasm, slides were stained for 10 s in a 
1.5% eosin (Fisher) solution. Residual staining solution was washed off in distilled water. 
The tissue was dehydrated in ascending ethanol gradient (50%, 70%, 95%, and 100%) and 
then incubated in xylenes (Fisher) for 5 min. The tissue slides were air-dried and mounted 
using toluene-based mounting medium (Fisher).   
2.7.2           Nuclear counterstaining for immunofluorescence microscopy  
Slides were washed with PBS for 5 minutes twice, incubated in 0.25% Triton X-100 
(Fisher) in PBS for 10 minutes, rinsed in PBS for 5 minutes, and then counterstained with 
1:1000 DAPI (Fisher). Slides were preserved in water-based mounting medium 
(Vectashield) and covered with a glass coverslip (Fisher).  
2.7.3           Image acquisition & analysis of slides 
Prepared slides were observed using EVOS FL Auto microscope (Life Technologies). 
DAPI UV (357-447 nm) filter was used to observe nuclei (blue), and RFP (red) were 
visualized under the 530-595 and 470-510 nm excitation filters, respectively. The 
percentage of lineage tracing was quantified using ImageJ. The area of lineage tracing or 
tumors was determined by outlining areas on ImageJ using the freehand area outlining tool. 
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Raw values were transferred to excel, and the percentage of lineage tracing was determined 
with the following formula ([total area of lineage tracing in tumours/total area of tumour] 
x 100). 
2.8       Organoid Culture 
 
The methods outlined below for intestinal organoid culture were modified from the 
methods originally presented by Sato et al., to increase efficiency (Sato et al., 2009). 
2.8.1           Experimental protocol 
Eight-week old Lgr5-DTR-eGFP;K19-CreERT;APCf/f and K19-CreERT;APCf/f mice 
were treated with 6 mg of tamoxifen via oral gavage. Two days post-tamoxifen treatment, 
small intestine and colonic tissues were cultured. R-spondin was removed from the media 
at day 5 to select for APCf/f organoids (normal organoids with intact APC require R-
spondin for survival, while APCf/f organoids do not). Organoids were passaged and treated 
with 20 ng/mL DT or vehicle (0.9% saline) from day 10 until day 30. At day 20, a subset 
of organoids had DT removed from the media (Figure 14). All experiments were repeated 
in triplicate.  
 
 
Figure 14 | Experimental protocol for in vitro Lgr5 ablation experiments. 
 
2.8.2           Isolation of intestinal crypts 
Fifteen cm of small intestine was flushed with PBS (Fisher). The intestine was then opened 
longitudinally and scraped firmly using a glass cover slip to remove the villi. Once scraped, 
the intestine was transferred to a centrifuge tube and washed vigorously with PBS. The 
intestine was resuspended in 10 mL of 2.5 mM EDTA (Fisher) in PBS and incubated at 
4°C in a rotator for one hour. The intestine was removed from solution and cut into 0.5 mm 
pieces and resuspended in 10 mL fetal bovine serum (FBS; Fisher) in PBS. To release 
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crypts from intestinal tissue fragments, the solution was vigorously pipetted 10-20 times. 
The solution was passed through a 70 M cell strainer to remove clumps and centrifuged 
at 800 rpm for 5 minutes. The pellet was resuspended in 5 mL DMEM (Fisher) containing 
Glutamax (Life Tech), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Hepes; Life 
Tech), and antibiotic/mycotic penicillin and streptomycin solution (Life Tech).  
2.8.3           Isolation of colonic crypts 
The entire colon was collected and flushed with PBS (Fisher). The colon was then opened 
longitudinally and scraped using a glass cover slip. Once scraped, the colon was transferred 
to a centrifuge tube and washed vigorously with PBS. The colon was resuspended in 10 
mL of 3 mM EDTA in PBS and incubated at 4°C in a rotator for one hour. The colon was 
removed from solution and cut into 0.5 mm pieces and resuspended in 10 mL of FBS. To 
release crypts from colonic tissue fragments, the solution was vigorously pipetted 15-25 
times. The solution was passed through a 100 µm cell strainer to remove clumps and 
centrifuged at 800 rpm for 5 minutes. The pellet was resuspended in 5 mL DMEM 
containing Glutamax, Hepes, and penicillin/streptomycin . 
2.8.4           Counting and seeding crypts 
The number of crypts in three 10 mL aliquots were counted and the appropriate volume of 
solution to seed the number of wells required was calculated. This volume was taken and 
resuspended in a 50:50 ratio with DMEM, followed by 50:50 dilution into the appropriate 
volume of Matrigel (Fisher). Ninety-six well plates were pre-warmed in the incubator prior 
to adding Matrigel.  
2.8.5           Organoid media 
Ninety-nine µL of organoid growth media (Table 5) was added to each well of the 96-well 







Table 5 | Recipe for complete organoid culture medium. 
Organoid Culture Medium Volume 
Penicillin/Streptomycin (100x ) 1 mL 
Hepes Buffer (100x) 1 mL 
Glutamax (100x) 1 mL 
N2 Supplement (100x) 1 mL 
B27 Supplement (50x) 2 mL 
Rspondin 2 mL 
DMEM 100 mL 
2.8.6           Diphtheria toxin treatment of organoids 
Organoids were treated with 20 ng/mL of Diphtheria toxin (DT) every two days from day 
10 to day 30 (Figure 15). Thirty µL aliquots of 2 ng/mL DT were prepared on ice from 
100X stock (Sigma). Aliquots were stored at -80°C until ready for use. One µL stock was 
added to 99 µL of media in each well. 
2.8.7           Passaging organoids 
Organoids were passaged every 10 days. Briefly, media was removed from each well and 
resuspended with 100 µL of cold DMEM. Matrigel was disrupted using a 200 µL pipette 
tip and pipetted up and down to free the organoids from the Matrigel. It was then pipetted 
into a 15 mL centrifuge tube, wells were rinsed with an additional 100 µL of cold DMEM 
and transferred to the tube. The organoids were centrifuged at 600 rpm for 5 minutes and 
the pellet was resuspended in growth media and re-seeded.  
2.8.8           Image acquisition & analysis of organoids 
Phase contrast images of organoid wells were obtained at days 10, 20, and 30 using EVOS 
FL Auto. Images were analyzed using ImageJ to quantify organoid number, area covered, 
as well as organoid-formation efficiency. Organoid-formation efficiency was defined as 
the ratio of the number of large colonies prior to passaging on day 20 and day 30 to the 
number of clones on day 10. The threshold area for total colonies on day 10 was set as <2 
x 105 m2 and for large colonies on day 30 as >2 x 105 m2 (equivalent to 20 cells). 
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2.9    Statistical analysis 
Descriptive data analysis was performed using Microsoft Excel. Comparison of means was 
carried out using GraphPad Prism 6.0. Following normality testing, the appropriate 






Chapter 3  
RESULTS 
3.1    K19 labels a CSC population in an APCmin model 
The presence of CSCs in CRC as well as many other cancers has become apparent over the 
past years. Different populations of CSCs have been proposed in the literature based on the 
expression of different markers. The most well-known population has been defined as 
expressing Lgr5. However, it remains to be determined whether more than one CSC 
population exists in tumours. Our preliminary data indicated that K19 may label a CSC 
population. Therefore, to investigate whether K19 marks CSC population in a familial 
model of colorectal cancer, K19-CreERT;R26TdTomato;APCmin mice were used. In this 
model, the TdTomato gene is fused with a stop codon cassette that is floxed by two loxP 
sites and is downstream of the R26 promoter region. In the absence of Cre, the TdTomato 
gene is not transcribed due to the stop codon and K19-driven fluorescence is not evident. 
When tamoxifen is administered, Cre is transcribed from the K19 promoter and the 
recombination of the loxP sites takes place leading to the excision of STOP cassette, 
followed by robust TdTomato fluorescence in K19 cells. To visualize K19 lineage tracing 
in a familial model of colorectal cancer, these mice were crossed with the APCmin mice. 
APCmin mice spontaneously generate tumours due to loss of heterozygosity of the APC 
allele. The majority of these tumours are found in the small intestine, however a small 
proportion arise in the colon. 
 
Tumours from 6-month old K19-CreERT;R26TdTomato;APCmin mice were analyzed for 
lineage tracing via histological analysis at 24 hours (n = 3) , 10 days (n = 2) and 4 weeks 
(n = 3) post-tamoxifen. The percentage of tumour area traced was calculated using ImageJ. 
In the small intestine, we found that a small proportion of tumour area was traced red 24 
hours after administration of tamoxifen (2.913 ± 1.547). From 24 hours to 10 days post-
tamoxifen, the red cell population expanded to encompass an average of 21.59  ± 2.143% 
of tumours, which was not significantly different compared to 4 weeks post-tamoxifen 
53 
 
(18.26 ± 3.903%) (Figure 15). This indicates that K19+ stem cells clonally expanded in 






























































Figure 15 | K19 labels a cancer stem cell population in the small intestine of APCmin 
mice. Experimental protocol (A) used to analyze K19+ cells in adenomas from K19-
CreERT;TdTomato;APCmin mice. Low power representative images of adenomas (Scale 
bars, 1000 m) in the small intestine at 24h (B), 10d (C) and 4 weeks (D) post tamoxifen 
are shown. High power view of adenomas (Scale bars, 200 m) in the small intestine are 
shown by immunofluorescence (left) and H&E (right).  (E) Quantification of K19+ cells 
traced in adenomas as area over time. There was a significant increase in the area of tumour 
traced between 24h and 10d, while no significant was observed between 10d and 4w. 
Although significant between 24h and 10d, it is important to note that this comparison may 
have low power due to an n of 2 in the 10d group. Data is presented as mean ± SE; n ≥ 2; 
analyzed by one-way ANOVA followed by Tukey’s post hoc test for multiple 
comparisons; * p < 0.05.  
 
3.2    K19 may label a CSC population in an AOM DSS model 
In order to address whether K19 labels a CSC population in a colitis-associated model of 
colorectal cancer, tumours from AOM/DSS treated K19-CreERT;TdTomato mice were 
analyzed for lineage tracing at 24 hours (n = 4) , 10 days (n = 4) and 4 weeks (n = 4) post-
tamoxifen. At 24 hours post-tamoxifen, a small proportion of tumour area was traced red 
(2.034 ± 1.551%). However, the proportion of red cells did not significantly increase from 
24 hours to 10 days (7.083 ± 2.692%) and 4 weeks (5.025 ± 4.085%) (Figure 16). These 




















































Figure 16 |  K19 may label a CSC population in an AOM DSS model. Experimental 
protocol (A) used to analyze K19+ cells in adenomas from AOM DSS treated K19-
CreERT;TdTomato mice. Low power representative images of adenomas (Scale bars, 1000 
m) in the colon at 24h (B), 10d (C) and 4 weeks (D) post-tamoxifen are shown. High 
power view of adenomas (Scale bars, 200 m) in the colon are shown by 
immunofluorescence (left) and H&E (right).  (E) Quantification of K19+ cells traced in 
adenomas as % area over time. No significant increase in the area of tumour traced over 
time was observed. Data is presented as mean ± SE; n = 4 per group; analyzed by one-way 
ANOVA; * p < 0.05. 
3.3    Ablation of Lgr5+ cells has no effect on tumour initiation 
or growth in vivo 
3.3.1           Diphtheria toxin dose characterization 
To confirm effective ablation of Lgr5+ cells in the intestine and colon of Lgr5-DTR-eGFP 
mice, 200 mL or 500ng of DT dissolved in 200 mL 0.9% saline was administered i.p. twice 
a week for two weeks (Figure 17; A). Twenty-four hours post administration of the last 
dose, tissues were prepared for histological analysis and analyzed for the presence of eGFP. 
As expected in the DT treated group, no eGFP (green) cells were present (Figure 17; B). 
This is compared to the saline treated group, where an abundance of eGFP (green cells) 




Figure 17 | Diphtheria toxin dose characterization. (A) Experimental protocol. (B) Low 
power representative immunofluorescence (Scale bars, 200 m) of small intestine and (C) 
colonic crypts in control (left) versus DT treated (right) Lgr5-DTR-eGFP mice (insets 20x 
magnification). As expected with administration of DT, all Lgr5+ cells are ablated. 
3.3.2           Ablation of Lgr5+ cells has no effect on tumour initiation or growth in vivo 
To examine the effect of Lgr5+ cell ablation on tumour initiation and growth in vivo, 
AOM/DSS treated WT and Lgr5-DTR-eGFP mice were administered 500 ng of DT or 
saline i.p twice a week, 3-weeks after AOM and until the end of the experiment (20 weeks 
post-AOM) (Figure 18, A). Mice do not express the diphtheria toxin receptor (DTR) and, 
therefore, are not susceptible to diphtheria toxin (DT). Thus expression of DTR in a Lgr5 
cell population allows for selective ablation of these cells upon DT administration. Cohorts 
of WT or Lgr5-DTR-eGFP experimental (DT treated) and control (saline treated) mice 
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and volume) at 20 weeks. As expected, histological analysis of adenomas from Lgr5 
negative WT mice revealed no GFP expression (Figure 18, B and C), while adenomas of 
Lgr5 positive mice treated with saline had robust GFP signal (Figure 18, D). This is in 
contrast to Lgr5 positive mice treated with DT that did not express GFP (Figure 18, E). 
These results indicate that Lgr5 + cells were effectively ablated. Importantly, when tumour 
burden was analyzed, no significant differences were observed in tumour number (Figure 
18, F) or tumour volume (Figure 18, G). This suggests that another CSC population besides 
Lgr5+ may contribute to tumour initiation and growth, as a complete loss of Lgr5+ cells 








































































































































Figure 18 | Ablation of Lgr5 cells has no effect on tumour initiation or growth. (A) 
Experimental protocol. Low power representative immunofluorescence (Scale bars, 1000 
m) of colonic tumours from (B) WT/Saline, (C) WT DT, (D) Lgr5+/Saline and (E) 
Lgr5+/DT treated mice are shown. High power images (Scale bars, 200 m) are shown by 
immunflourescence (left) and histology (right) for colonic tumours  (F) The number of 
tumours and (G) tumour volume did not vary significantly between groups; p > 0.05. 
Results presented as mean ± SE; n ≥ 10. One-way ANOVA was used for statistical 
analyses.  
3.4   Intestinal and colonic K19+ APC floxed organoids give   
rise to spheroids 
Asfaha et al. (2015) reported that when intestinal crypts from K19-CreERT;APCf/f mice 
were cultured following tamoxifen administration, recombined APC floxed organoids 
appeared as spherical structures, which were easily distinguishable morphologically from 
normal budding crypt structures. However, it was unclear whether colonic APC floxed 
crypts cultured from K19-CreERT;APCf/f mice would give rise to spheroids in vitro. To 
investigate this, intestinal and colonic crypts from K19-CreERT;APCf/f mice were 
cultured 48 hours after tamoxifen administration (Figure 19, A).  As expected intestinal 
crypts contained APC floxed K19+ cells gave rise to spheroid structures that were easily 
distinguished from normal wild-type budding crypt structures (Figure 19, B). Similarly, 
colonic crypts from recombined APC floxed K19+ cells appeared as spheroid structures, 
which were also easily distinguishable morphologically from normal budding crypt 
structures (Figure 19, C). Moreover, K19+ cells in which APC was floxed produced 






Figure 19 | Intestinal and colonic K19+ floxed organoids give rise to spheroids. (A) 
Experimental protocol. (B) Representative phase contrast images of intestinal and colonic 




























































Type (WT) organoids display a budding morphology while APCf/f organoids form 
spheroids. Scale bars, day two (100 m), day four (200 m) and day eight (400 m). 
3.5       Ablation of Lgr5+ cells has no effect on intestinal      or 
colonic spheroid growth 
To determine the effect of Lgr5+ cell ablation on tumour growth in established K19 
tumours in vitro, Lgr5-DTR-eGFP mice were crossed to K19-CreERT;APCf/f mice to 
generate Lgr5-DTR-eGFP;K19-CreERT;APCf/f  (L5DKA) mice. Briefly, treatment of 
these L5DKA mice with tamoxifen induces a loss of APC specifically in K19 cells and 
allows for ablation of Lgr5+ cells with DT administration. Our lab previously demonstrated 
that following tamoxifen treatment, intestinal cells cultured from L5DKA mice give rise to 
spherical “tumour” organoids in vitro in 48 hours. To determine the effects of Lgr5+ cell 
ablation on K19 spheroids, both intestinal and colonic crypts from tamoxifen treated 
L5DKA mice were cultured to monitor their growth and spheroid forming capacity with 
administration of DT. The organoids generated were treated with 20 ng/mL of DT 
(experimental) or vehicle (control) from d10 to d30. Additionally, a subset of spheroids 
was treated with DT from d10 to d20 and vehicle from d20 to d30 (Figure 20, A). 
Subsequently, the total number of spheroids, spheroid area and spheroid formation capacity 
were analyzed over time for small intestine and colonic spheroids. In the small intestine 
and colon, there was no significant difference (p > 0.05) in the total number of spheroids, 
tumour area or organoid forming efficiency between control, DT or DT removed groups at 
D10, D20 or D30 (Figure 20 and 21, C, D, E). Interestingly, there also was no change in 
tumour area between all groups (p > 0.05) (Figure 20 and 21 D).  
 
As a control, intestinal and colonic crypts from tamoxifen-treated K19-CreERT;APCf/f 
mice were cultured at the same time as L5DKA mice using the same protocol to monitor 
their growth and spheroid forming capacity with administration of DT or vehicle. My 
results show no significant difference (p > 0.05) in the total number of spheroids, tumour 
area or organoid forming efficiency between control, DT or DT removed groups at D10, 
D20 or D30 (Figure 22 and 23, C, D, E). This demonstrates the DT administration itself 
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has no effect on intestinal or colonic spheroids, providing further support to the findings in 
Figure 20.  
 
These results highlight that with a complete loss of Lgr5+ cells in K19+ APC floxed 
intestinal and colonic spheroids, there is no effect on tumour number, growth, or organoid 
forming efficiency. This suggests that another CSC population besides Lgr5+ CSC may 
establish intestinal and colonic tumours and contribute to tumour growth. Moreover, 
organoid-forming efficiency reflects the surviving fraction of stem cells among crypt cells 
as organoids are derived from stem cells. Therefore, despite continuous ablation of Lgr5+ 
CSCs (even after passaging), another CSC population must exist in intestinal and colonic 
tumours, that allows spheroids to establish themselves. Taken together, these results 
suggest that K19+ APC floxed spheroids are composed of a heterogeneous population 






































Figure 20 | Ablation of Lgr5 cells has no effect on small intestine spheroid growth. (A) 
Experimental protocol. (B) Representative phase contrast images of organoid cultures 
(scale bars, 1000 m). (C) Quantification of the number of spheroids, spheroid area (D), 
and spheroid forming efficiency (E). No significant differences were observed between 
treatment groups. Results presented as mean ± SE; n = 3. A two-way ANOVA followed 
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Figure 21 | Ablation of Lgr5 cells has no effect on colonic spheroid growth. (A) 
Experimental protocol. (B) Representative phase contrast images (scale bars, 1000 m) of 
organoid cultures. (C) Quantification of the number of spheroids, spheroid area (D), and 
spheroid formation efficiency (E). Results presented as mean ± standard error of the mean; 
n = 3. No significant differences were observed between treatment groups.  A two-way 




































Figure 22 | Diphtheria toxin has no effect on WT small intestine spheroids. (A) 
Experimental protocol. (B) Representative images of organoid cultures (scale bars, 1000 
m). (C) Quantification of the number of spheroids, spheroid area (D), and spheroid 
formation efficiency (E). Results presented as mean ± standard error of the mean; n = 3. 
No significant differences were observed between treatment groups.  A two-way ANOVA 



































Figure 23 | Diphtheria toxin has no effect on WT colonic spheroids. (A) Experimental 
protocol. (B) Representative images of organoid cultures (scale bars, 1000 m). (C) 
Quantification of the number of spheroids, spheroid area (D), and spheroid formation 
efficiency (E). Results presented as mean ± standard error of the mean; n = 3. No significant 
differences were observed between treatment groups.  A two-way ANOVA followed by 
Tukey’s post-hoc test for multiple comparisons was used for statistical analyses. 
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Chapter 4  
DISCUSSION 
 
The purpose of this thesis was to determine if the colorectal cancer stem cell pool 
encompasses different stem cell phenotypes, much like the normal intestinal epithelium. 
To identify additional CSCs, I analyzed genetic lineage tracing from K19+ cells in vivo in 
multiple mouse models of CRC. To provide further evidence for the presence of multiple 
cell types, my experiments were followed by ablation of a known CSCs (marked by Lgr5 
expression) in established tumours in vivo and in vitro. My rationale for this approach was 
based on accumulating evidence which implicated the role of multiple CSCs in CRC, as 
well as our lab’s preliminary findings that K19 may label a CSC population (unpublished 
studies). My findings support my initial hypothesis that K19 identifies a CSC population 
distinct from the previously identified Lgr5+ CSCs. Although further studies are necessary 
to determine whether K19 is essential for tumour growth, data presented here provides 
insight into the seemingly diverse CSC pool present in CRC tumours.  
4.1       K19 labels a CSC population in an APCmin model 
Previous data from our lab identified K19 as a stem cell marker in the small intestine and 
colon, distinct from Lgr5+ cells that can give rise to tumours (Asfaha et al. 2015). 
Moreover, K19 is amplified in solid tumours making it an ideal candidate CSC marker 
(Lapouge et al., 2011). As such, I hypothesized that K19 would label a CSC population in 
a mouse model of FAP-CRC. Genetic lineage tracing was used to evaluate CSC potential 
(i.e. the ability to self-renew and differentiate) to circumvent the drawbacks of traditional 
serial transplantation assays.  
 
To determine whether K19 labels a CSC population, I analyzed the percentage of intestinal 
and colonic tumour area traced over time in K19-CreERT;R26TdTomato;APCmin mice. 
In the small intestine, I found that a small tumour area (2%) was traced red at 24 hours 
after tamoxifen administration, indicating that it was derived from the labeled K19 cells. 
Interestingly, this clonal population expanded significantly to make up approximately 20% 
of tumours by day 10. No further increases were noted at 4 weeks. These set of results 
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indicate that single traced clones are capable of giving rise to cell lineages that are labeled 
long-term. Long-term labeling is suggestive of self-renewal, given the highly proliferative 
nature of tumours. As is the case with Lgr5+ CSCs, sorted K19+ intestinal tumour cells 
have not been studied in a serial transplantation assay to determine self-renewal or 
tumourigenic capacity. It should be noted that applicability of serial transplantation assays 
to solid tumours is controversial. The appearance of Paneth cells in traced lineages suggests 
the ability of K19 CSCs to differentiate. However, immunohistochemical staining to 
confirm the presence of Paneth cells or other differentiated lineages has not been carried 
out. Regardless, the ability of K19 to form single traced clones capable of giving rise to 
cell lineages (that appear to contain Paneth cells with eosinophilic granules in histological 
sections) and are labeled long term suggests multipotency and self-renewal. Consequently, 
my findings represent the first study to identify K19 as a marker for CSCs in intestinal 
tumours of APCmin mice.  
 
Interestingly, an elegant study conducted by de Sousa e Melo et al demonstrated that Lgr5+ 
ablation restricts primary tumour growth but does not result in tumour regression (de Sousa 
e Melo et al., 2017). The authors go on to propose that tumours may be maintained by an 
Lgr5 negative population capable of replenishing the Lgr5+ CSC pool, which leads to rapid 
initiation of tumour growth upon removal of treatment (de Sousa e Melo et al., 2017). This 
is similar to what has been observed in the normal intestine, where homeostasis is 
maintained by reserve stem cell populations if Lgr5 cells are lost. In contrast to primary 
lesions, they found that Lgr5 plays a critical role in the development of metastasis as little 
evidence of metastatic lesions was found post Lgr5 ablation (de Sousa e Melo et al., 2017). 
Together, this data highlights that different CSC populations may play different roles in 
primary versus metastatic tumour growth or even across different stages of CRC. 
Moreover, when taking into consideration that K19 labels a CSC population in the APCmin 
model, our data provides support that K19 labels a CSC population in primary tumour sites. 
The APCmin mouse model does not metastasize and is most representative of early stage 
CRCs. Of note, the model used in the study by de Sousa e Melo et al contained mutations 
in APC as well as KRAS. However, it would be highly relevant and interesting for future 
studies to investigate the role of K19 and Lgr5 at different stages of CRC progression. 
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Additionally, future studies should investigate whether K19 is essential in primary tumours 
through genetic ablation studies.  
4.2       K19 may label a CSC population in the AOM/DSS 
model of CRC  
 
To investigate whether K19 labels a CSC population in a colitis-associated model of CRC, 
I analyzed genetic lineage tracing from K19-CreERT;R26TdTomato mice treated with 
AOM/DSS at various time points post-tamoxifen administration. I hypothesized that K19 
would label a CSC population in this model and that K19+ cell-derived clones would 
expand and persist in tumours. Initially, I observed a small population of clones in the 
tumours. However, the clones did not expand to give rise to more differentiated cell types 
over time but persisted. These results were not expected. There are several possible 
explanations for this observation as the CSC phenotype is likely influenced by a variety of 
factors, including the tissue microenvironment, and the accumulation of mutations at 
various progressive stages. A study conducted by de Sousa e Melo et al. demonstrated that 
Lgr5 labelled CSCs are influenced by both tissue location and tumour microenvironment 
(de Sousa e Melo et al., 2017). Contrary to their initial expectations, ablation of Lgr5 CSCs 
in primary tumours did not lead to tumour regression. However, they did find that Lgr5 
cells play a role in the establishment of liver metastasis. The authors suggested that 
different “biological cues” mediated CSCs in primary and metastatic sites leading to 
proliferation of certain CSC populations. In accordance with this study and the results I 
obtained using the K19 APCmin model, K19 may play a more important role in the earlier 
stages of CRC. A key distinction between my studies and that by de Sousa e Melo et al. as 
well as other is that only APC is mutated in the APCmin model compared to -catenin as 
well as KRAS alterations in in the AOM DSS models (Takahashi and Wakabayashi, 2004). 
These studies highlight the importance of the tumour microenvironment (inflammation, 
primary vs metastatic sites) and genetic mutations (for example, APC vs APC/KRAS) in 






4.3       Ablation of Lgr5+ cells has no effect on tumour 
initiation or growth  
Previous research has suggested that the CSC pool likely encompasses different cell 
phenotypes in a dynamic equilibrium with each other and that elimination of Lgr5+ CSCs 
might disrupt tumour biology to alter tumour growth but not eradicate disease. These 
findings, in combination with my results from sections 3.1, prompted me to examine the 
effects of Lgr5+ CSC ablation on tumour initiation and growth in an AOM DSS model. I 
hypothesized that ablation of Lgr5 cells would have no effect on tumour initiation or 
growth. Previously, it was shown that short-term administration of high doses of diphtheria 
toxin was associated with liver toxicity and subsequent lethality in 10 days (Asfaha et al., 
2015). Therefore, it was necessary to first establish a protocol that effectively ablated Lgr5 
cells at a lower dose for long-term use. Subsequently, I found that 500 ng of DT 
administered twice a week effectively ablated Lgr5 cells. This was indicated by the 
presence of Lgr5-GFP+ cells in the vehicle-treated group versus no Lgr5-GFP+ cells in the 
DT-treated group (Figure 17). Moreover, no detrimental effect on intestinal or animal 
viability was observed and ensuing long term experiments on the effects of Lgr5 ablation 
throughout tumour initiation and growth were conducted.  
In support of my hypothesis, I found that Lgr5+ CSCs are dispensable for tumour initiation 
as well as maintenance. Furthermore, efficiency of ablation was confirmed through 
analysis of histological sections post-ablation. I observed Lgr5-GFP+ cells in vehicle-
treated Lgr5-DTR-eGFP mice, while no Lgr5-GFP+ cells were observed in Lgr5-DTR-
eGFP mice treated with DT or untreated controls. The results from this study demonstrate 
for the first time that more than one CSC population functionally contributes to tumour 
initiation and growth in a colitis-associated model of CRC. Similarly, these findings are 
also supported by two recent studies by independent groups that demonstrated little effect 
on tumours following ablation of Lgr5 cells. In one study de Sousa e Melo et al., showed 
that ablation of Lgr5 in primary tumours had no effect on tumour growth suggesting an 
Lgr5 negative population is capable maintaining tumour growth (de Sousa e Melo et al., 
2017). In another study, it was shown that Lgr5 ablation was only effective temporarily 
(Shimokawa et al., 2017). Furthermore, targeted ablation of Lgr5+ cells using an Lgr5 
antibody directed chemotherapeutic in the APCmin mouse model had no effect on tumour 
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burden (Junttila et al., 2015). These studies in combination with my findings demonstrate 
that in some tumour models, the CSC pool encompasses different cell phenotypes. 
Unlike the present study, previous studies investigating the ablation of Lgr5 in tumour 
models did not focus on tumour initiation or utilize immunocompetent mice. As discussed 
earlier, the tumour microenvironment plays an important role in regulating CSC function. 
This is of the utmost importance when considering the phenotype of CSCs, particularly in 
colitis-associated cancer - as the immune system plays a critical role in regulation of the 
tissue microenvironment.  It is important to note, that animal models do not recapitulate all 
types of human colorectal cancer and these results do not recapitulate the results that might 
occur at different stages of CRC. As such, the results obtained in this study are likely 
reflective of this particular model.  
4.4   Intestinal and colonic K19+ APC floxed organoids give 
rise to spheroids  
In 2009, Sato et al. demonstrated that single Lgr5-eGFP+ CBC cells isolated using FACS 
and plated in a Matrigel-based three-dimensional culture system gave rise to self-renewing 
epithelial organoids (Sato et al., 2009). This method was a monumental breakthrough in 
the field of intestinal stem cells. Later on, it was adapted to culture Lgr5+ CBC that 
contained a mutation in the APC gene. Interestingly, loss of APC function in Lgr5 cells 
gave rise to organoids that had a cystic morphology, compared to the normal budding 
structure. It was later determined that these organoids were representative of early stage 
colorectal cancers. Subsequently, the culture protocol was modified, allowing for the 
addition of several mutations found in later stages of colorectal cancer, as well as the 
eventual culture of human colorectal tumours (Sato et al., 2011; Shimokawa et al., 2017). 
Since 2009, multiple “tumour organoid” models have been adapted from this initial 
protocol.  
 
In particular, Asfaha et al. adapted the Sato protocol to establish a tumour organoid 
protocol derived from intestinal crypts of K19-CreERT;APCf/f mice. Treatment of these 
mice with tamoxifen induced loss of APC specifically in K19+ cells, and intestinal crypts 
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cultured from these mice gave rise to tumour spheroids in vitro after 48 hours (Asfaha et 
al., 2015). However, it remained unclear whether colonic crypts from these mice would 
give rise to colonic tumour spheroids. Based on the expression of K19+ ISCs in both the 
normal and intestinal and colonic crypt, I hypothesized that loss of APC in colonic K19 
cells would give rise to colonic tumour spheroids, similar to the small intestine. My results 
showed that when colonic intestinal crypts were cultured two days after in vivo tamoxifen 
administration, large cystic structures appeared. The same phenomenon was observed in 
intestinal crypts that were cultured identically. As described previously, APC floxed 
organoids are easily distinguishable from non-recombined crypts that form normal budding 
structures (as shown in Figure 19). Of note, K19+ APC floxed organoids are maintained in 
the absence of R-spondin. In normal, non-mutated organoids, R-spondin is required for 
amplification of Wnt signalling and organoid survival. Accordingly, when R-spondin was 
removed (Figures 20 and 21) from both intestinal and colonic organoids, only APCf/f 
spheroids survived. Thus indicating that both colonic and intestinal tumour spheroids were 
derived from K19-CreERT;APCf/f crypts. It is important to note, however, that nuclear co-
localization of β-catenin has not been validated in this model. Despite this limitation, 
selection of tumour organoids with R-spondin provides functional evidence of APC loss 
of function.  
 
4.5   Ablation of Lgr5+ cells has no effect on intestinal or 
colonic spheroids 
 
As mentioned in section 4.3, previous research has suggested that the CSC pool likely 
encompasses a dynamic cell population as elimination of Lgr5+ CSCs in some CRC 
models has limited effects. My results in a colitis-associated model of CRC are supportive 
of this notion.  However, it remains unknown whether Lgr5 CSCs are dispensable in 
established tumours representative of early stages of CRC, and unrelated to inflammation. 
As such, I hypothesized that loss of Lgr5 in established APCf/f tumours (model of early 
stage CRC) would have no effect on spheroid number, growth or formation efficiency. I 
crossed K19-CreERT;APCf/f mice to Lgr5-DTR-eGFP mice to generate an Lgr5-DTR-
eGFP;K19-CreERT;APCf/f model. As mentioned in the previous section, when intestinal 
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and colonic crypts are cultured after tamoxifen treatment, cystic tumour organoids form 
due to the loss of APC in K19+ cells. Additionally, the presence of Lgr5-DTR-eGFP allows 
for the conditional and specific ablation of Lgr5 cells in established K19+ cell derived 
APCf/f tumours. Therefore, I treated organoid cultures with DT once tumour organoids 
were established for 10 days. Following the 10 days, DT was removed from a subset of 
organoids to determine the effects on growth and stem cell activity. As a control, K19-
CreERT;APCf/f mice were cultured at the same time to ensure DT alone did not have an 
effect on tumour number, organoid area or spheroid formation efficiency. My results show 
that ablation of Lgr5 cells in intestinal and colonic tumour spheroids had no effect on the 
number, area or spheroid formation efficiency between control and DT groups across all 
time points (Figure 20, 21). Importantly, no effect on spheroid number and area indicates 
that an Lgr5- cell population is contributing to spheroid growth and Lgr5 cells are 
dispensable in this model. This highlights that another CSC population must reside in these 
spheroids that allows continuous establishment despite constant ablation of Lgr5+ cells 
even after passaging. This is consistent with my findings presented in section 3.3.2. 
Additionally, my results from section 3.1, highlight that in an APCmin model, where only 
APC is mutated, K19 labels a CSC population, thereby corroborating the existence of 
another CSC population in the early stages of CRC. Future studies should directly examine 
K19 lineage tracing in addition to Lgr5 ablation with an APCmin or APCf/f model to 
conclusively determine this.  
 
Unexpectedly, there was no difference between all groups when DT was removed from a 
subset of spheroids. This is in contrast to the findings of de Sousa e Melo et al., in which 
discontinuation of DT mediated Lgr5 ablation led to rapid tumour organoid regrowth (de 
Sousa e Melo et al., 2017). Importantly, this is likely due to differences in experimental 
models. Our model is reflective of the early stages of CRC, in which only APC is mutated. 
In contrast, their model is representative of later stages of CRC and included mutations in 
the KRAS, p53 and SMAD pathways. These results suggest K19 may be an important 
target in prevention or treatment of earlier stages of CRC.  Although unlikely, another 
potential explanation is that the dose of DT used did not sufficiently ablate Lgr5+ cells. As 
such, future studies should confirm ablation of Lgr5+ cells possibly by 
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immunohistochemical or mRNA analysis of DT-treated vs control organoids. It is 
important to note, however, that the dose of DT used in my study (20 ng) was determined 
to effectively ablate Lgr5 CBC cells in intestinal organoids by mRNA analysis (Asfaha et 
al., 2015). Interestingly, in this published study, mRNA analysis also revealed an increase 
in K19 mRNA expression upon DT mediated ablation of Lgr5. This suggests that the same 
phenomenon may be occurring in established APCf/f spheroids in vitro, although, this 
needs further verification. Lastly, no differences were observed between control, DT, or 
DT removed groups in intestinal and colonic spheroids derived from Lgr5-DTR-eGFP 
negative K19;APCf/f controls (Figure 22, 23). This suggests that administration of DT 
alone has no effect on spheroid number, growth or formation efficiency. Taken together, 
these findings provide evidence that more than one CSC population exists in an early CRC 
model. This highlights that in some models, the CSC population represents a dynamic cell 
population in delicate equilibrium. 
4.6 Implications and future directions  
 
The studies outlined here advance our understanding of cancer biology in two very 
meaningful ways: (1) I determined that the CSC pool encompasses a variety of cell 
phenotypes; and (2) I determined the relative contributions of these populations to tumour 
growth by ablating a known CSC population. These two concepts have important 
implications for the design of anti-tumour therapies. On the one hand, drugs targeted at 
malignant sub-populations with CSC properties may have important therapeutic effects. 
However, these effects may vary depending on how permissive the host tissue is to 
dynamic interconversion between CSC phenotypes and functional differences that may 
exist between CSC populations. Therefore, drugs or radiation aimed too narrowly at only 
one CSC phenotype might translate to only transient, short-lived clinical benefits and 
eventually fail to cure patients. Although these concepts increase the level of complexity 
for developing new cancer treatments, my research may lead to an improved understanding 
of the systems that governs the growth, multi- lineage differentiation, dynamic turnover 
and regenerative response to tumour tissues. Our lab has developed unique transgenic 
mouse models that are clinically relevant because they are immunocompetent and allow us 
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to selectively kill a known cancer stem cell in vivo. Moreover, my findings suggest that a 
diverse population of CSCs exist in early and colitis-associated colorectal cancer mouse 
models. This may suggest that CSCs are governed by the tumour microenvironment or 
genetic mutations. Consequently, this improved understanding of CSCs will help define 
new molecular targets for different phenotypic subgroups of CSCs or block the sources of 
CSCs simultaneously to achieve complete elimination of cancer. 
 
Despite the insights into colorectal cancer CSCs in this thesis, several questions could not 
be directly answered. Importantly, although it was demonstrated that K19 labels a cancer 
stem cell population in the APCmin model, it remains unknown whether K19 is essential 
for tumour growth or whether K19 is influenced by the tumour microenvironment directly. 
These questions could be answered through genetic ablation studies of K19 and 
manipulation of the tumour microenvironment through in vitro studies. Additionally, the 
question of whether K19 CSCs drive chemotherapy or radiation resistance could not be 
answered in this thesis. Future experiments evaluating the tumorigenicity of K19 in 
different CRC models could provide more evidence to answer this question.  
 
The results in this thesis warrant further exploration and direct comparison of different 
CSC phenotypes observed in various CRC models as well as stages of progression. This 
would help to determine essential therapeutic targets as well as the relative contributions 
of each population to therapy resistance, metastasis and patient survival. Therefore, future 
experiments should focus on the identification, evaluation and comparison of verified CSC 
populations to answer this question. 
4.7 Limitations  
The first aim of this thesis was to determine if K19 labels a cancer stem cell population. A 
potential limitation of aim one is the confirmation of CSC multipotency in lineage tracing 
models of CRC. While my initial lineage tracing experiments revealed that K19 labels a 
CSC population in the APCmin model, possibly capable of giving rise to Paneth cells, 
further experiments are necessary to determine multipotency. In this sense, 
immunohistochemical analysis of differentiated cell markers (e.g. lysozyme) in tumours 
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would complement these studies. Likewise, throughout this thesis, genetic lineage tracing 
analysis was used to determine stemness. However, it would be interesting to assess the 
CSC potential of these cell populations using serial transplantation assays as a secondary 
measure of the ability of these cells to self-renew. Perhaps, this may be conducted in vitro 
using serial culture of organoids. However, this approach may not be as powerful as genetic 
lineage tracing. It is also important to note that the cre-lox lineage tracing models utilized 
in this study demonstrate genetic mosaicism. As a result of this, it is likely that the K19+ 
population labelled in my studies is reflective of only a subset of the true population. The 
CSC marker identified in this thesis was not characterized as distinct from Lgr5 cells 
through the appropriate lineage tracing/genetic ablation studies because of the extensive 
nature of the studies. Most importantly, the long-term side effects or targeting these novel 
CSC populations was not investigated. This is an important issue to consider before 
investigating these novel CSC markers as potential therapeutic targets, as K19+ cells share 
expression with both normal and cancerous tissues. 
 
The second aim of this thesis was to assess the effects of Lgr5+ cell ablation on tumour 
growth in vivo and in vitro. In the in vivo model, no effect was observed on tumour 
initiation and growth. However, the mouse model used in this experiment does not 
recapitulate all types of human colorectal cancer and at all stages. Therefore, the results 
obtained are likely only reflective of this particular model. Importantly, this limitation is 
applicable to every mouse CRC model used in this thesis. As such human colorectal cancer 
organoids or additional animal models should be used to investigate these processes at 
various stages and types of CRC.  
 
When analyzing the ablation of Lgr5 in vitro, I found no effect on spheroid number, growth 
or formation efficiency. Although the dose used was previously demonstrated to be 
effective by Asfaha et al., a potential limitation of this experiment is that confirmation of 
DT-mediated ablation by mRNA or immunohistochemical analysis was not carried out. 
Furthermore, it would have been optimal to conduct cell viability assays to determine the 
appropriate dose of DT. Lastly, in the organoid formation assays clumps of cells were 
plated rather than individual cells. It may have been more accurate to generate single cell 
83 
 
cultures from organoids which may be achieved by using TrypLE, however, this process 
is much costlier and time consuming.  
4.8 Conclusion 
The cancer stem cell hypothesis suggests that CSCs are the driving force behind tumour 
progression and metastasis, making them ideal therapeutic targets. Previous research 
identified Lgr5 as an important marker of CSCs in CRC. However, effective treatment of 
CRC patients depends on the identification of cells responsible for tumour initiation and 
progression. This was precisely the motivation of my studies. I found that K19 labels 
mouse intestinal CSCs in tumours arising in a model that recapitulates the early stages of 
human CRC. Moreover, selective ablation of Lgr5 had no effect on tumour initiation or 
growth in vivo or in vitro. These results clearly demonstrate that additional CSC 
populations, beyond Lgr5+ cells, exist in intestinal and colonic tumors and are important 








Afify, A., Purnell, P., & Nguyen, L. (2009). Role of CD44s and CD44v6 on human breast 
cancer cell adhesion, migration, and invasion. Experimental and molecular pathology, 
86(2), 95-100. 
 
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). 
Prospective identification of tumorigenic breast cancer cells. Proceedings of the National 
Academy of Sciences, 100(7), 3983-3988. 
 
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999). Notch signaling: cell fate 
control and signal integration in development. Science, 284(5415), 770-776. 
 
Asfaha, S., Hayakawa, Y., Muley, A., Stokes, S., Graham, T. A., Ericksen, R. E., ... & 
Guha, C. (2015). Krt19+/Lgr5− cells are radioresistant cancer-initiating stem cells in the 
colon and intestine. Cell stem cell, 16(6), 627-638. 
 
Ashton-Rickardt, P. G., Dunlop, M. G., Nakamura, Y., Morris, R. G., Purdie, C. A., Steel, 
C. M., ... & Wyllie, A. H. (1989). High frequency of APC loss in sporadic colorectal 
carcinoma due to breaks clustered in 5q21-22. Oncogene, 4(10), 1169-1174. 
 
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., ... & Rich, J. N. 
(2006). Glioma stem cells promote radioresistance by preferential activation of the DNA 
damage response. Nature, 444(7120), 756. 
 
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, 
M., ... & Clevers, H. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. 
Nature, 457(7229), 608. 
 
Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial homeostasis and 
regeneration. Nature reviews Molecular cell biology, 15(1), 19. 
 
Barker, N., Van Es, J. H., Kuipers, J., Kujala, P., Van Den Born, M., Cozijnsen, M., ... & 
Clevers, H. (2007). Identification of stem cells in small intestine and colon by marker gene 
Lgr5. Nature, 449(7165), 1003. 
 
Barker, N., Bartfeld, S., & Clevers, H. (2010). Tissue-resident adult stem cell populations 
of rapidly self-renewing organs. Cell stem cell, 7(6), 656-670. 
 
Barker, N., van Oudenaarden, A., & Clevers, H. (2012). Identifying the stem cell of the 
intestinal crypt: strategies and pitfalls. Cell stem cell, 11(4), 452-460. 
 





Blank, M., Klussmann, E., Krüger‐Krasagakes, S., Schmitt‐Gräff, A., Stolte, M., 
Bornhoeft, G., ... & Riecken, E. O. (1994). Expression of MUC2‐mucin in colorectal 
adenomas and carcinomas of different histological types. International journal of cancer, 
59(3), 301-306. 
 
Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nature medicine, 3(7), 730. 
 
Bromfield, G., Dale, D., De, P., Newman, K., Rahal, R., & Shaw, A. (2017). Canadian 
cancer statistics, special topic: Predictions of the future burden of cancer in canada. 
Toronto, ON: Canadian Cancer Society, Government of Canada. 
 
Chen, R., Nishimura, M. C., Bumbaca, S. M., Kharbanda, S., Forrest, W. F., Kasman, I. 
M., ... & Modrusan, Z. (2010). A hierarchy of self-renewing tumor-initiating cell types in 
glioblastoma. Cancer cell, 17(4), 362-375. 
 
Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. 
(2012). A restricted cell population propagates glioblastoma growth after chemotherapy. 
Nature, 488(7412), 522. 
 
Cheng, H., & Leblond, C. P. (1974). Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine V. Unitarian theory of the origin of the 
four epithelial cell types. American Journal of Anatomy, 141(4), 537-561. 
 
Chu, P., Clanton, D. J., Snipas, T. S., Lee, J., Mitchell, E., Nguyen, M. L., ... & Peach, R. 
J. (2009). Characterization of a subpopulation of colon cancer cells with stem cell‐like 
properties. International journal of cancer, 124(6), 1312-1321. 
 
Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nature 
medicine, 17(3), 313. 
 
Clevers, H. (2013). The intestinal crypt, a prototype stem cell compartment. Cell, 154(2), 
274-284. 
 
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer research, 65(23), 10946-
10951. 
Colnot, S., Niwa-Kawakita, M., Hamard, G., Godard, C., Le Plenier, S., Houbron, C., ... & 
Perret, C. (2004). Colorectal cancers in a new mouse model of familial adenomatous 
polyposis: influence of genetic and environmental modifiers. Laboratory investigation, 
84(12), 1619. 
 




Dalerba, P., Kalisky, T., Sahoo, D., Rajendran, P. S., Rothenberg, M. E., Leyrat, A. A., ... 
& Zabala, M. (2011). Single-cell dissection of transcriptional heterogeneity in human colon 
tumors. Nature biotechnology, 29(12), 1120. 
 
Dalton, W. B., & Yang, V. W. (2007). Mitotic origins of chromosomal instability in 
colorectal cancer. Current colorectal cancer reports, 3(2), 59-64. 
 
Davies, R. J., Miller, R., & Coleman, N. (2005). Colorectal cancer screening: prospects for 
molecular stool analysis. Nature Reviews Cancer, 5(3), 199. 
 
Deng, S., Yang, X., Lassus, H., Liang, S., Kaur, S., Ye, Q., ... & Connolly, D. C. (2010). 
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase 
isoform 1 (ALDH1), in human epithelial cancers. PloS one, 5(4), e10277. 
 
Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012). Defining the 
mode of tumour growth by clonal analysis. Nature, 488(7412), 527. 
 
Du, L., Wang, H., He, L., Zhang, J., Ni, B., Wang, X., ... & Chen, Q. (2008). CD44 is of 
functional importance for colorectal cancer stem cells. Clinical cancer research, 14(21), 
6751-6760. 
 
e Melo, F. D. S., Kurtova, A. V., Harnoss, J. M., Kljavin, N., Hoeck, J. D., Hung, J., ... & 
Dijkgraaf, G. J. (2017). A distinct role for Lgr5+ stem cells in primary and metastatic colon 
cancer. Nature, 543(7647), 676. 
 
Evans, J. P., Sutton, P. A., Winiarski, B. K., Fenwick, S. W., Malik, H. Z., Vimalachandran, 
D., ... & Kitteringham, N. R. (2016). From mice to men: Murine models of colorectal 
cancer for use in translational research. Critical reviews in oncology/hematology, 98, 94-
105. 
 
Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 
61(5), 759-767. 
 
Foersch, S., & Neurath, M. F. (2014). Colitis-associated neoplasia: molecular basis and 
clinical translation. Cellular and molecular life sciences, 71(18), 3523-3535. 
 
Foulds, L. (1954). The experimental study of tumor progression: a review. Cancer 
research, 14(5), 327-339. 
 
Fredebohm, J., Boettcher, M., Eisen, C., Gaida, M. M., Heller, A., Keleg, S., ... & Giese, 
N. A. (2012). Establishment and characterization of a highly tumourigenic and cancer stem 





Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., ... & Uraoka, T. 
(2016). A colorectal tumor organoid library demonstrates progressive loss of niche factor 
requirements during tumorigenesis. Cell Stem Cell, 18(6), 827-838. 
 
Gregorieff, A., & Clevers, H. (2005). Wnt signaling in the intestinal epithelium: from 
endoderm to cancer. Genes & development, 19(8), 877-890. 
 
Grabowski, P., SchÖnfelder, J., AHNERT‐HILGER, G. U. D. R. U. N., FOSS, H. D., Stein, 
H., Berger, G., ... & ScherÜbl, H. (2004). Heterogeneous expression of neuroendocrine 
marker proteins in human undifferentiated carcinoma of the colon and rectum. Annals of 
the New York Academy of Sciences, 1014(1), 270-274. 
 
Gryfe, R., Bapat, B., Gallinger, S., Swallow, C., Redston, M., & Couture, J. (1997). 
Molecular biology of colorectal cancer. Current problems in cancer, 21(5), 233-299. 
 
Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., ... & 
Sargeant, L. (1991). Identification and characterization of the familial adenomatous 
polyposis coli gene. Cell, 66(3), 589-600. 
 
Gunawardene, A. R., Corfe, B. M., & Staton, C. A. (2011). Classification and functions of 
enteroendocrine cells of the lower gastrointestinal tract. International journal of 
experimental pathology, 92(4), 219-231. 
 
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009). Cancer stem cells: mirage or 
reality?. Nature medicine, 15(9), 1010. 
 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. cell, 
144(5), 646-674. 
 
Huang, E. H., Hynes, M. J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., ... & 
Boman, B. M. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant 
human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. 
Cancer research, 69(8), 3382-3389. 
 
He, X. C., Zhang, J., Tong, W. G., Tawfik, O., Ross, J., Scoville, D. H., ... & Mishina, Y. 
(2004). BMP signaling inhibits intestinal stem cell self-renewal through suppression of 
Wnt–β-catenin signaling. Nature genetics, 36(10), 1117. 
 
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., ... & 
Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumor growth 
and metastatic activity in human pancreatic cancer. Cell stem cell, 1(3), 313-323. 
 
Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., ... & Fukata, 
M. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the 




Jasperson, K. W., Tuohy, T. M., Neklason, D. W., & Burt, R. W. (2010). Hereditary and 
familial colon cancer. Gastroenterology, 138(6), 2044-2058. 
 
Joo, K. M., Kim, S. Y., Jin, X., Song, S. Y., Kong, D. S., Lee, J. I., ... & Jin, J. (2008). 
Clinical and biological implications of CD133-positive and CD133-negative cells in 
glioblastomas. Laboratory investigation, 88(8), 808. 
 
Junttila, M. R., Mao, W., Wang, X., Wang, B. E., Pham, T., Flygare, J., ... & Eastham-
Anderson, J. (2015). Targeting LGR5+ cells with an antibody-drug conjugate for the 
treatment of colon cancer. Science translational medicine, 7(314), 314ra186-314ra186. 
 
Kaestner, K. H., Silberg, D. G., Traber, P. G., & Schütz, G. (1997). The mesenchymal 
winged helix transcription factor Fkh6 is required for the control of gastrointestinal 
proliferation and differentiation. Genes & development, 11(12), 1583-1595. 
 
Kemper, K., Prasetyanti, P. R., De Lau, W., Rodermond, H., Clevers, H., & Medema, J. P. 
(2012). Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. 
Stem cells, 30(11), 2378-2386. 
 
Kettunen, H. L., Kettunen, A. S., & Rautonen, N. E. (2003). Intestinal immune responses 
in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer research, 63(16), 
5136-5142. 
 
Keysar, S. B., & Jimeno, A. (2010). More than markers: biological significance of cancer 
stem cell-defining molecules. Molecular cancer therapeutics, 1535-7163. 
 
Kinzler, K. W., Nilbert, M. C., Su, L. K., Vogelstein, B., Bryan, T. M., Levy, D. B., ... & 
McKechnie, D. (1991). Identification of FAP locus genes from chromosome 5q21. Science, 
253(5020), 661-665. 
 
Kim, M. P., Fleming, J. B., Wang, H., Abbruzzese, J. L., Choi, W., Kopetz, S., ... & Gallick, 
G. E. (2011). ALDH activity selectively defines an enhanced tumor-initiating cell 
population relative to CD133 expression in human pancreatic adenocarcinoma. PloS one, 
6(6), e20636. 
 
Kobayashi, S., Yamada‐Okabe, H., Suzuki, M., Natori, O., Kato, A., Matsubara, K., ... & 
Hashimoto, E. (2012). LGR5‐positive colon cancer stem cells interconvert with drug‐
resistant LGR5‐negative cells and are capable of tumor reconstitution. Stem cells, 30(12), 
2631-2644. 
 
Koo, B. K., & Clevers, H. (2014). Stem cells marked by the R-spondin receptor LGR5. 
Gastroenterology, 147(2), 289-302. 
 
Kosinski, C., Stange, D. E., Xu, C., Chan, A. S., Ho, C., Yuen, S. T., ... & Chen, X. (2010). 
Indian hedgehog regulates intestinal stem cell fate through epithelial− mesenchymal 




Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., ... & Dick, 
J. E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into 
SCID mice. Nature, 367(6464), 645. 
 
Lapouge, G., Youssef, K. K., Vokaer, B., Achouri, Y., Michaux, C., Sotiropoulou, P. A., 
& Blanpain, C. (2011). Identifying the cellular origin of squamous skin tumors. 
Proceedings of the National Academy of Sciences, 201012720. 
 
Li, Z. (2013). CD133: a stem cell biomarker and beyond. Experimental hematology & 
oncology, 2(1), 17. 
 
Livet, J., Weissman, T. A., Kang, H., Draft, R. W., Lu, J., Bennis, R. A., ... & Lichtman, J. 
W. (2007). Transgenic strategies for combinatorial expression of fluorescent proteins in 
the nervous system. Nature, 450(7166), 56. 
 
Leblond, C. P., & Stevens, C. E. (1948). The constant renewal of the intestinal epithelium 
in the albino rat. The Anatomical Record, 100(3), 357-377. 
 
Luche, H., Weber, O., Rao, T. N., Blum, C., & Fehling, H. J. (2007). Faithful activation of 
an extra‐bright red fluorescent protein in “knock‐in” Cre‐reporter mice ideally suited for 
lineage tracing studies. European journal of immunology, 37(1), 43-53. 
 
Marhaba, R., & Zöller, M. (2004). CD44 in cancer progression: adhesion, migration and 
growth regulation. Journal of molecular histology, 35(3), 211-231. 
 
Marsh, K. A., Stamp, G. W., & Kirkland, S. C. (1993). Isolation and characterization of 
multiple cell types from a single human colonic carcinoma: tumourigenicity of these cell 
types in a xenograft system. The Journal of pathology, 170(4), 441-450. 
 
Mashimo, H., Wu, D. C., Podolsky, D. K., & Fishman, M. C. (1996). Impaired defense of 
intestinal mucosa in mice lacking intestinal trefoil factor. Science, 274(5285), 262-265. 
 
Medema, J. P., & Vermeulen, L. (2011). Microenvironmental regulation of stem cells in 
intestinal homeostasis and cancer. Nature, 474(7351), 318. 
 
Medema, J. P. (2013). Cancer stem cells: the challenges ahead. Nature cell biology, 15(4), 
338. 
 
Middelhoff, M., Westphalen, C. B., Hayakawa, Y., Yan, K. S., Gershon, M. D., Wang, T. 
C., & Quante, M. (2017). Dclk1-expressing tuft cells: critical modulators of the intestinal 





Miyaki, M., Konishi, M., Kikuchi-Yanoshita, R., Enomoto, M., Igari, T., Tanaka, K., ... & 
Maeda, Y. (1994). Characteristics of somatic mutation of the adenomatous polyposis coli 
gene in colorectal tumors. Cancer research, 54(11), 3011-3020. 
 
Moll, R., Franke, W. W., Schiller, D. L., Geiger, B., & Krepler, R. (1982). The catalog of 
human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. 
Cell, 31(1), 11-24. 
 
Moolenbeek, C., & Ruitenberg, E. J. (1981). The ‘Swiss roll’: a simple technique for 
histological studies of the rodent intestine. Laboratory animals, 15(1), 57-60. 
 
Moser A. R., Pitot H. C., Dove W. F. A dominant mutation that predisposes to intestinal 
neoplasia in the mouse. Science (Washington DC), 247: 322-324,1990. 
Muñoz, J., Stange, D. E., Schepers, A. G., Van De Wetering, M., Koo, B. K., Itzkovitz, S., 
... & Myant, K. (2012). The Lgr5 intestinal stem cell signature: robust expression of 
proposed quiescent ‘+ 4’cell markers. The EMBO journal, 31(14), 3079-3091. 
Nakanishi, Y., Seno, H., Fukuoka, A., Ueo, T., Yamaga, Y., Maruno, T., ... & Isomura, A. 
(2013). Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature 
genetics, 45(1), 98. 
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012). Cancer stem cells: an evolving 
concept. Nature Reviews Cancer, 12(2), 133. 
Nowell, P. C. (1976). The clonal evolution of tumor cell populations. Science, 194(4260), 
23-28. 
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106. 
O'Connell, M. J., Campbell, M. E., Goldberg, R. M., Grothey, A., Seitz, J. F., Benedetti, J. 
K., ... & Sargent, D. J. (2008). Survival following recurrence in stage II and III colon 
cancer: findings from the ACCENT data set. Journal of Clinical Oncology, 26(14), 2336-
2341. 
Ogden, A. T., Waziri, A. E., Lochhead, R. A., Fusco, D., Lopez, K., Ellis, J. A., ... & 
McCormick, P. C. (2008). Identification of A2B5+ CD133− tumor-initiating cells in adult 
human gliomas. Neurosurgery, 62(2), 505-515. 
Pham, P. V., Phan, N. L., Nguyen, N. T., Truong, N. H., Duong, T. T., Le, D. V., ... & 
Phan, N. K. (2011). Differentiation of breast cancer stem cells by knockdown of CD44: 
promising differentiation therapy. Journal of translational medicine, 9(1), 1. 
Pierce, G. B., Nakane, P. K., Martinez-Hernandez, A., & Ward, J. M. (1977). 
Ultrastructural comparison of differentiation of stem cells of murine adenocarcinomas of 




Plaks, V., Kong, N., & Werb, Z. (2015). The cancer stem cell niche: how essential is the 
niche in regulating stemness of tumor cells?. Cell stem cell, 16(3), 225-238. 
Polakis, P. (1999). The oncogenic activation of β-catenin. Current opinion in genetics & 
development, 9(1), 15-21. 
Polakis, P. (2000). Wnt signaling and cancer. Genes & development, 14(15), 1837-1851. 
Potten, C. S., Booth, C., & Pritchard, D. M. (1997). The intestinal epithelial stem cell: the 
mucosal governor. International journal of experimental pathology, 78(4), 219-243. 
Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. 
N., ... & Kinzler, K. W. (1992). APC mutations occur early during colorectal 
tumorigenesis. Nature, 359(6392), 235. 
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. 
J. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 
593. 
Radtke, F., Clevers, H., & Riccio, O. (2006). From gut homeostasis to cancer. Current 
molecular medicine, 6(3), 275-289. 
Ragnhammar, P., Hafström, L., Nygren, P., & Glimelius, B. (2001). A systematic overview 
of chemotherapy effects in colorectal cancer. Acta oncologica, 40(2-3), 282-308. 
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De 
Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. 
Nature, 445(7123), 111. 
Richardson, G. D., Robson, C. N., Lang, S. H., Neal, D. E., Maitland, N. J., & Collins, A. 
T. (2004). CD133, a novel marker for human prostatic epithelial stem cells. Journal of cell 
science, 117(16), 3539-3545. 
Rizk, P., & Barker, N. (2012). Gut stem cells in tissue renewal and disease: methods, 
markers, and myths. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 
4(5), 475-496. 
Rosenberg, D. W., Giardina, C., & Tanaka, T. (2008). Mouse models for the study of colon 
carcinogenesis. Carcinogenesis, 30(2), 183-196. 
Sarkar, F. H., Li, Y., Wang, Z., & Kong, D. (2009). Pancreatic cancer stem cells and EMT 
in drug resistance and metastasis. Minerva chirurgica, 64(5), 489. 
Sangiorgi, E., & Capecchi, M. R. (2008). Bmi1 is expressed in vivo in intestinal stem cells. 
Nature genetics, 40(7), 915. 
92 
 
Sansom, O. J., Reed, K. R., Hayes, A. J., Ireland, H., Brinkmann, H., Newton, I. P., ... & 
Clarke, A. R. (2004). Loss of Apc in vivo immediately perturbs Wnt signaling, 
differentiation, and migration. Genes & development, 18(12), 1385-1390. 
Sasaki, N., Sachs, N., Wiebrands, K., Ellenbroek, S. I., Fumagalli, A., Lyubimova, A., ... 
& Li, V. S. (2016). Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ 
stem cells in colon. Proceedings of the National Academy of Sciences, 113(37), E5399-
E5407. 
Sato, T., Vries, R. G., Snippert, H. J., Van De Wetering, M., Barker, N., Stange, D. E., ... 
& Clevers, H. (2009). Single Lgr5 stem cells build crypt–villus structures in vitro without 
a mesenchymal niche. Nature, 459(7244), 262. 
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G., Van Es, J. H., Van Den Brink, S., ... & 
Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, 
adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology, 141(5), 1762-
1772. 
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., ... & 
Yang, Q. (2004). MYC inactivation uncovers pluripotent differentiation and tumour 
dormancy in hepatocellular cancer. Nature, 431(7012), 1112. 
Schepers, A. G., Snippert, H. J., Stange, D. E., van den Born, M., van Es, J. H., van de 
Wetering, M., & Clevers, H. (2012). Lineage tracing reveals Lgr5+ stem cell activity in 
mouse intestinal adenomas. Science, 337(6095), 730-735. 
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., 
... & Rupec, R. A. (2013). Intestinal tumorigenesis initiated by dedifferentiation and 
acquisition of stem-cell-like properties. Cell, 152(1), 25-38. 
Shimokawa, M., Ohta, Y., Nishikori, S., Matano, M., Takano, A., Fujii, M., ... & Sato, T. 
(2017). Visualization and targeting of LGR5+ human colon cancer stem cells. Nature, 
545(7653), 187. 
Shmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., ... & 
Chadburn, A. (2008). CD133 expression is not restricted to stem cells, and both CD133+ 
and CD133–metastatic colon cancer cells initiate tumors. The Journal of clinical 
investigation, 118(6), 2111-2120. 
Sikandar, S. S., Pate, K. T., Anderson, S., Dizon, D., Edwards, R. A., Waterman, M. L., & 
Lipkin, S. M. (2010). NOTCH signaling is required for formation and self-renewal of 
tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. 
Cancer research, 0008-5472. 
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., ... & Dirks, P. 
B. (2004). Identification of human brain tumour initiating cells. nature, 432(7015), 396. 
93 
 
Spit, M., Koo, B. K., & Maurice, M. M. (2018). Tales from the crypt: intestinal niche 
signals in tissue renewal, plasticity and cancer. Open biology, 8(9), 180120. 
Staal, F. J., Weerkamp, F., Baert, M. R., van den Burg, C. M., van Noort, M., de Haas, E. 
F., & van Dongen, J. J. (2004). Wnt target genes identified by DNA microarrays in 
immature CD34+ thymocytes regulate proliferation and cell adhesion. The Journal of 
Immunology, 172(2), 1099-1108. 
Stevens, C. E., & Leblond, C. P. (1947). Rate of renewal of the cells of the intestinal 
epithelium in the rat. The Anatomical record, 97(3), 373. 
 
Su, Y., Qiu, Q., Zhang, X., Jiang, Z., Leng, Q., Liu, Z., ... & Jiang, F. (2010). Aldehyde 
dehydrogenase 1 A1–positive cell population is enriched in tumor-initiating cells and 
associated with progression of bladder cancer. Cancer Epidemiology and Prevention 
Biomarkers, 19(2), 327-337. 
 
Su L. K., Kinzler K. W., Vogelstein B., Preisinger A. C., Moser A. R., Luongo C., Gould 
K. A., Dove W. F. Multiple intestinal neoplasia caused by a mutation in the murine 
homolog of the APC gene. Science (Washington DC), 256: 668-670, 1992 
Sullivan, J. P., Minna, J. D., & Shay, J. W. (2010). Evidence for self-renewing lung cancer 
stem cells and their implications in tumor initiation, progression, and targeted therapy. 
Cancer and Metastasis Reviews, 29(1), 61-72. 
Takahashi, M., Fukuda, K., Sugimura, T., & Wakabayashi, K. (1998). β-Catenin is 
frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat 
colon tumors. Cancer research, 58(1), 42-46. 
Takahashi, M., Nakatsugi, S., Sugimura, T., & Wakabayashi, K. (2000). Frequent 
mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane. 
Carcinogenesis, 21(6), 1117-1120. 
Takahashi, M., & Wakabayashi, K. (2004). Gene mutations and altered gene expression in 
azoxymethane‐induced colon carcinogenesis in rodents. Cancer science, 95(6), 475-480. 
Takeda, N., Jain, R., LeBoeuf, M. R., Wang, Q., Lu, M. M., & Epstein, J. A. (2011). 
Interconversion between intestinal stem cell populations in distinct niches. Science, 
334(6061), 1420-1424. 
Tanaka, T., Kohno, H., Suzuki, R., Yamada, Y., Sugie, S., & Mori, H. (2003). A novel 
inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and 
dextran sodium sulfate. Cancer science, 94(11), 965-973. 
Tanei, T., Morimoto, K., Shimazu, K., Kim, S. J., Tanji, Y., Taguchi, T., ... & Noguchi, S. 
(2009). Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 
expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for 
breast cancers. Clinical cancer research, 15(12), 4234-4241. 
94 
 
Tian, H., Biehs, B., Warming, S., Leong, K. G., Rangell, L., Klein, O. D., & de Sauvage, 
F. J. (2011). A reserve stem cell population in small intestine renders Lgr5-positive cells 
dispensable. Nature, 478(7368), 255. 
Tomita, H., Tanaka, K., Tanaka, T., & Hara, A. (2016). Aldehyde dehydrogenase 1A1 in 
stem cells and cancer. Oncotarget, 7(10), 11018. 
Van der Flier, L. G., van Gijn, M. E., Hatzis, P., Kujala, P., Haegebarth, A., Stange, D. E., 
... & van Es, J. H. (2009). Transcription factor achaete scute-like 2 controls intestinal stem 
cell fate. Cell, 136(5), 903-912. 
Van der Flier, L. G., Sabates–Bellver, J., Oving, I., Haegebarth, A., De Palo, M., Anti, M., 
... & Clevers, H. (2007). The intestinal Wnt/TCF signature. Gastroenterology, 132(2), 628-
632. 
Van Der Flier, L. G., & Clevers, H. (2009). Stem cells, self-renewal, and differentiation in 
the intestinal epithelium. Annual review of physiology, 71, 241-260. 
Van Der Kraak, L., Gros, P., & Beauchemin, N. (2015). Colitis-associated colon cancer: Is 
it in your genes?. World journal of gastroenterology, 21(41), 11688. 
Vermeulen, L., & Snippert, H. J. (2014). Stem cell dynamics in homeostasis and cancer of 
the intestine. Nature Reviews Cancer, 14(7), 468-480. 
Visvader, J. E. (2011). Cells of origin in cancer. Nature, 469(7330), 314. 
Wang, J., Sakariassen, P. Ø., Tsinkalovsky, O., Immervoll, H., Bøe, S. O., Svendsen, A., 
... & Molven, A. (2008). CD133 negative glioma cells form tumors in nude rats and give 
rise to CD133 positive cells. International journal of cancer, 122(4), 761-768. 
Wang, L., Su, W., Liu, Z., Zhou, M., Chen, S., Chen, Y., ... & Han, Z. (2012). CD44 
antibody-targeted liposomal nanoparticles for molecular imaging and therapy of 
hepatocellular carcinoma. Biomaterials, 33(20), 5107-5114. 
West, A. B., Isaac, C. A., Carboni, J. M., Morrow, J. S., Mooseker, M. S., & Barwick, K. 
W. (1988). Localization of villin, a cytoskeletal protein specific to microvilli, in human 
ileum and colon and in colonic neoplasms. Gastroenterology, 94(2), 343-352. 
Wirtz, S., Neufert, C., Weigmann, B., & Neurath, M. F. (2007). Chemically induced mouse 
models of intestinal inflammation. Nature protocols, 2(3), 541. 
World Cancer Research Fund/American Institute for Cancer Research. (2011). Continuous 
update project report. Food, nutrition, physical activity, and the prevention of colorectal 
cancer. 
Yamashita, K., Katoh, H., & Watanabe, M. (2013). The homeobox only protein homeobox 




Yan, K. S., Chia, L. A., Li, X., Ootani, A., Su, J., Lee, J. Y., ... & Sangiorgi, E. (2012). The 
intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. 
Proceedings of the National Academy of Sciences, 109(2), 466-471. 
Yanai, H., Atsumi, N., Tanaka, T., Nakamura, N., Komai, Y., Omachi, T., ... & Tokuyama, 
Y. (2017). Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to 
tumor propagation via clonal expansion. Scientific reports, 7, 41838. 
Yoon, C., Park, D. J., Schmidt, B., Thomas, N. J., Lee, H. J., Kim, T. S., ... & Yoon, S. S. 
(2014). CD44 expression denotes a subpopulation of gastric cancer cells in which 
Hedgehog signaling promotes chemotherapy resistance. Clinical cancer research. 
Yu, Y., Ramena, G., & Elble, R. C. (2012). The role of cancer stem cells in relapse of solid 
tumors. Front Biosci (Elite Ed), 4(4), 1528-1541. 
Zasadil, L. M., Britigan, E. M., Ryan, S. D., Kaur, C., Guckenberger, D. J., Beebe, D. J., 
... & Weaver, B. A. (2016). High rates of chromosome missegregation suppress tumor 
progression but do not inhibit tumor initiation. Molecular biology of the cell, 27(13), 1981-
1989. 
Zeuner, A., Todaro, M., Stassi, G., & De Maria, R. (2014). Colorectal cancer stem cells: 



























DIPHTHERIA TOXIN Sigma 
TAQQ FROGGAMIX FroggaBio 
TAE Fisher 
NUCLEASE FREE H2O FroggaBio 
AGAROSE Fisher 
ETHIDIUM BROMIDE Sigma 
DSS Gojira 
CORN OIL Sigma 
PBS Fisher 





MOUNTING MEDIUM DAPI Vectashield 
MOUNTING MEDIUM H&E Toluene - Fisher 
EDTA Fisher 
TRITON X 100 Fisher 
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GLUTAMAX Life Tech 
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APPENDIX II: PREPARATION OF SOLUTIONS 
 
 
Tail Lysis Buffer – 25mM NaOH/0.2mM EDTA 
10M NaOH  125mL 
0.5M EDTA  20 mL 
MilliQ Water  49.8 mL 
 
1.     Add 125 mL of 10M NaOH + 20mL 0.5M EDTA to 50 mL centrifuge tube. 
2.     Fill up to 50 mL of MilliQ water. 
 
Tail Neutralization Buffer – 40mM Tris HCL (pH 5.5) 
Tris HCL  315.12 mg 
MilliQ water  50 mL 
 
1.     Add 315.12 mg of Tris HCL to 50 mL centrifuge tube. 
2.     Fill MilliQ water up to 45 mL 
3.     Adjust pH to 5.5 using 10M NaOH and HCL 





APPENDIX III: PCR CONDITIONS AND PRIMERS 
 
K19-CreERT 
CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 55 30s 
Extension 72 30s 
Final Extension 72 7min 1 
Hold 4 ∞ 
 
Primers:  




CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 60 30s 
Extension 72 30s 
Final Extension 72 7min 1 








CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 61 30s 
Extension 72 30s 
100 
 
Final Extension 72 7min 1 




WT F – AAG GGA GCT GCA GTG GAG TA   
WT R - CCG AAA ATC TGT GGG AAG TC   
 
Mut F – GGC ATT AAA GCA GCG TAT CC 




      
CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 61 30s 
Extension 72 30s 
Final Extension 72 7min 1 
Hold 4 ∞   
Primers: 
F – AGAAGCCGGTGGAGAAGAG 
R - GCTTGTGGCTTGGAGGATAA 




CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 55 30s 
Extension 72 1min 
Final Extension 72 1min 1 
Hold 4 ∞ 
 
Primers: 
F – TTC TGA GAA AGA CAG AAG TTA 







CYCLE STEP TEMP (°C) TIME CYCLES 
Initial Denaturation 94 5min 1 
Denaturation 94 30s 35 
Annealing 58 40s 
Extension 65 1:10 min 
Final Extension 65 3min 1 
Hold 4 ∞   
 
Primers: 
F - CACTGCATTCTAGTTGTGG 
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